PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
28100326-7	2017	After treatment with the dopamine receptor agonist pramipexole dihydrochloride, the catechol-O-methyltransferase inhibitor entacapone, and vitamin B6, the boy showed mild improvements in hypotonia, blepharoptosis, and oculogyric crisis.	entacapone	123-133	catechol-O-methyltransferase	Homo sapiens	84-112
27522262-7	2016	(2) Inhibition of catechol-O-methyltransferase enzyme by entacapone decreased the antiproliferative effects of fisetin and quercetin.	entacapone	57-67	catechol-O-methyltransferase	Homo sapiens	18-46
27456338-8	2016	Since some amount of entacapone can cross the blood-brain barrier, this reagent may enhance L-DOPA transportation by inhibiting COMT and increase the astrocyte-mediated neuroprotective effects of L-DOPA on dopaminergic neurons.	entacapone	21-31	catechol-O-methyltransferase	Homo sapiens	128-132
27089846-6	2016	It is noteworthy that the inhibition constants (Ki) of tolcapone and entacapone against bilirubin-O-glucuronidation in human liver microsomes (HLM) are determined as 0.68muM and 30.82muM, respectively, which means that the inhibition potency of tolcapone on UGT1A1 mediated bilirubin-O-glucuronidation in HLM is much higher than that of entacapone.	entacapone	69-79	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	258-264
27089846-7	2016	Furthermore, the potential risks of tolcapone or entacapone via inhibition of human UGT1A1 were quantitatively predicted by the ratio of the areas under the plasma drug concentration-time curve (AUC).	entacapone	49-59	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	84-90
26582803-2	2016	Inhibitors of COMT, such as tolcapone and entacapone, are used clinically in the treatment of Parkinson"s disease.	entacapone	42-52	catechol-O-methyltransferase	Homo sapiens	14-18
27089846-1	2016	Tolcapone and entacapone are two potent catechol-O-methyltransferase (COMT) inhibitors with a similar skeleton and displaying similar pharmacological activities.	entacapone	14-24	catechol-O-methyltransferase	Homo sapiens	40-68
27089846-1	2016	Tolcapone and entacapone are two potent catechol-O-methyltransferase (COMT) inhibitors with a similar skeleton and displaying similar pharmacological activities.	entacapone	14-24	catechol-O-methyltransferase	Homo sapiens	70-74
27089846-4	2016	The results demonstrated that both tolcapone and entacapone exhibited inhibitory effects on UGT1A1, UGT1A7, UGT1A9 and UGT1A10.	entacapone	49-59	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	92-98
27089846-4	2016	The results demonstrated that both tolcapone and entacapone exhibited inhibitory effects on UGT1A1, UGT1A7, UGT1A9 and UGT1A10.	entacapone	49-59	UDP glucuronosyltransferase family 1 member A7	Homo sapiens	100-106
27089846-4	2016	The results demonstrated that both tolcapone and entacapone exhibited inhibitory effects on UGT1A1, UGT1A7, UGT1A9 and UGT1A10.	entacapone	49-59	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	108-114
27089846-4	2016	The results demonstrated that both tolcapone and entacapone exhibited inhibitory effects on UGT1A1, UGT1A7, UGT1A9 and UGT1A10.	entacapone	49-59	UDP glucuronosyltransferase family 1 member A10	Homo sapiens	119-126
25834315-1	2015	AIM: To study the effects of entacapone, a catechol-O-methyltransferase inhibitor, on colon motility and electrolyte transport in Parkinson"s disease (PD) rats.	entacapone	29-39	catechol-O-methyltransferase	Rattus norvegicus	43-71
27074629-3	2016	Tolcapone and entacapone are potent inhibitors of catechol-O-methyl transferase (COMT) for the treatment of Parkinson"s disease.	entacapone	14-24	catechol-O-methyltransferase	Homo sapiens	50-79
27074629-3	2016	Tolcapone and entacapone are potent inhibitors of catechol-O-methyl transferase (COMT) for the treatment of Parkinson"s disease.	entacapone	14-24	catechol-O-methyltransferase	Homo sapiens	81-85
26692288-3	2016	In randomized phase III trials, oral carbidopa/levodopa ER was significantly more effective than placebo with regard to improving motor symptoms and activities of daily living in patients with early PD after 30 weeks" treatment, and provided significantly greater reductions in daily "off-time" in patients with advanced PD than immediate-release (IR) carbidopa/levodopa or carbidopa/levodopa IR plus entacapone after a treatment period of 13 and 2 weeks, respectively, without increasing troublesome dyskinesia.	entacapone	401-411	epiregulin	Homo sapiens	56-58
26844013-1	2016	Tolcapone and entacapone are catechol-O-methyltransferase (COMT) inhibitors developed as adjunct therapies for treating Parkinson"s disease.	entacapone	14-24	catechol-O-methyltransferase	Homo sapiens	29-57
26844013-1	2016	Tolcapone and entacapone are catechol-O-methyltransferase (COMT) inhibitors developed as adjunct therapies for treating Parkinson"s disease.	entacapone	14-24	catechol-O-methyltransferase	Homo sapiens	59-63
26295926-1	2015	Entacapone is an inhibitor of catechol-O-methyltransferase (COMT) and is being used to extend the therapeutic effect of levodopa in patients with advanced and fluctuating Parkinson"s disease.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	30-58
26295926-1	2015	Entacapone is an inhibitor of catechol-O-methyltransferase (COMT) and is being used to extend the therapeutic effect of levodopa in patients with advanced and fluctuating Parkinson"s disease.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	60-64
25639262-2	2015	In the STRIDE-PD study, prostate cancer developed in 9 patients (3.7%) receiving levodopa/carbidopa with entacapone, a catechol-O-methyltransferase inhibitor, versus 2 cases (0.9%) without entacapone.	entacapone	105-115	catechol-O-methyltransferase	Homo sapiens	119-147
25834315-8	2015	The COMT inhibitor entacapone inhibited contraction of the PD rat longitudinal muscle in a dose-dependent manner.	entacapone	19-29	catechol-O-methyltransferase	Rattus norvegicus	4-8
25834315-16	2015	The beta2 adrenoceptor is involved in the entacapone-induced inhibition of colon motility.	entacapone	42-52	adrenoceptor beta 2	Rattus norvegicus	4-22
25301937-5	2015	For example, similarly to the human UGT1A10, dUGT1A11 exhibited high glucuronidation activity toward the 3-OH of 17-beta-estradiol, 17-alpha-estradiol, and ethinylestradiol, and also conjugated the drug entacapone.	entacapone	203-213	UDP glucuronosyltransferase family 1 member A10	Homo sapiens	36-43
25435314-5	2015	We found that systemic and local administration of the COMT inhibitor entacapone significantly improves learning performance.	entacapone	70-80	catechol-O-methyltransferase	Rattus norvegicus	55-59
24928742-7	2014	Methylated metabolites catalyzed by catechol-O-methyl transferase (COMT) were observed mainly in the in vitro incubation with rat liver cytosol, which was verified by using a COMT specific inhibitor entacapone and supported by molecular docking analysis.	entacapone	199-209	catechol-O-methyltransferase	Rattus norvegicus	36-65
24928742-7	2014	Methylated metabolites catalyzed by catechol-O-methyl transferase (COMT) were observed mainly in the in vitro incubation with rat liver cytosol, which was verified by using a COMT specific inhibitor entacapone and supported by molecular docking analysis.	entacapone	199-209	catechol-O-methyltransferase	Rattus norvegicus	67-71
24928742-7	2014	Methylated metabolites catalyzed by catechol-O-methyl transferase (COMT) were observed mainly in the in vitro incubation with rat liver cytosol, which was verified by using a COMT specific inhibitor entacapone and supported by molecular docking analysis.	entacapone	199-209	catechol-O-methyltransferase	Rattus norvegicus	175-179
24148818-2	2014	Entacapone and tolcapone, COMT inhibitors, are used to mitigate the symptoms of Parkinson"s disease.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	26-30
24830331-2	2014	Entacapone, a peripheral inhibitor of catechol-O-methyltransferase (COMT), reduces this motor complication by prolonging the effect of levodopa.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	38-66
24830331-2	2014	Entacapone, a peripheral inhibitor of catechol-O-methyltransferase (COMT), reduces this motor complication by prolonging the effect of levodopa.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	68-72
24148818-9	2014	In conclusion, the combination of EGCG and entacapone/tolcapone synergistically inhibited the growth of lung cancer cells in culture, and the mechanistic basis for this synergy is likely due in part to inhibition of COMT with resultant increase in the levels of unmetabolized EGCG.	entacapone	43-53	catechol-O-methyltransferase	Homo sapiens	216-220
24229565-4	2014	Hence, inhibition of COMT activity with entacapone should reverse PFC dopaminergic transmission.	entacapone	40-50	catechol-O-methyltransferase	Homo sapiens	21-25
23265352-9	2013	This result supports our hypothesis, at least in patients with levodopa-resistant FOG, and shows that the co-administration of L-DOPS and entacapone could be a new strategy for FOG treatment.	entacapone	138-148	zinc finger protein, FOG family member 1	Homo sapiens	82-85
23673910-4	2013	Pharmacokinetic trials of oral LD/dopa decarboxylase inhibitor (DDCI) formulations with and without the catechol-O-methyltransferase inhibitor, entacapone, showed that repeated administration with entacapone causes an increase in both the maximum concentration (Cmax) and time to Cmax (Tmax) of LD.	entacapone	144-154	catechol-O-methyltransferase	Homo sapiens	104-132
23673910-4	2013	Pharmacokinetic trials of oral LD/dopa decarboxylase inhibitor (DDCI) formulations with and without the catechol-O-methyltransferase inhibitor, entacapone, showed that repeated administration with entacapone causes an increase in both the maximum concentration (Cmax) and time to Cmax (Tmax) of LD.	entacapone	197-207	catechol-O-methyltransferase	Homo sapiens	104-132
23281915-8	2013	LDh and LDl were administered in acute challenges in combination with vehicle and, for LDl, with the COMT inhibitor entacapone (5, 15 and 45 mg/kg).	entacapone	116-126	catechol-O-methyltransferase	Homo sapiens	101-105
23104937-2	2013	Pregnant Sprague-Dawley rats were given entacapone (a catechol-O-methyltransferase inhibitor) by gavage from the 10th to the 20th day of pregnancy.	entacapone	40-50	catechol-O-methyltransferase	Rattus norvegicus	54-82
23265352-6	2013	Of the 16 PD patients with FOG who completed this study, group 1 (n=6) received L-DOPS co-administered with entacapone, which is a COMT inhibitor used worldwide as an anti-parkinson drug, group 2 (n=5) received entacapone alone, and group 3 (n=5) received L-DOPS alone.	entacapone	108-118	catechol-O-methyltransferase	Homo sapiens	131-135
23265352-9	2013	This result supports our hypothesis, at least in patients with levodopa-resistant FOG, and shows that the co-administration of L-DOPS and entacapone could be a new strategy for FOG treatment.	entacapone	138-148	zinc finger protein, FOG family member 1	Homo sapiens	177-180
23948989-3	2013	Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a DDCI.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	14-42
22999990-6	2012	The method was successfully validated and applied to the pharmacokinetic study when oral administration of FCE to rats with or without co-giving a COMT inhibitor, entacapone.	entacapone	163-173	catechol-O-methyltransferase	Rattus norvegicus	147-151
22999990-8	2012	Furthermore, AUC of luteolin was significantly increased by entacapone, while that of chrysoeriol was decreased by entacapone, which revealed COMT might play an important role in the disposition of luteolin in rats after dosing of FCE.	entacapone	115-125	catechol-O-methyltransferase	Rattus norvegicus	142-146
20641250-15	2004	In clinical studies, AAAD is commonly inhibited with carbidopa, whereas COMT is blocked by entacapone and nitecapone.	entacapone	91-101	catechol-O-methyltransferase	Homo sapiens	72-76
22860182-7	2012	Finally, novel non-nitrocatechol COMT inhibitors displayed less potent uncoupling of the mitochondrial membrane potential (MMP) compared to tolcapone as well as nonhepatotoxic entacapone, thus mitigating the risk of hepatotoxicity.	entacapone	176-186	catechol-O-methyltransferase	Homo sapiens	33-37
22123108-2	2012	At the present time, tolcapone and entacapone are the only two COMT inhibitors available in the market.	entacapone	35-45	catechol-O-methyltransferase	Homo sapiens	63-67
21280081-1	2011	OBJECTIVE: In Parkinson disease (PD), the selective C-O-methyltransferase (COMT) inhibitor entacapone prolongs the effect of levodopa on motor symptoms (ON time) by increasing its bioavailability.	entacapone	91-101	catechol-O-methyltransferase	Homo sapiens	75-79
21999147-9	2011	The COMT activity inhibiting drugs including tolcapone and entacapone, have shown promising potential as they selectively modulate dopaminergic transmission.	entacapone	59-69	catechol-O-methyltransferase	Homo sapiens	4-8
21856742-3	2011	Nonetheless, using the specific substrates entacapone and zidovudine (AZT) for UGT1A9 and UGT2B7, respectively, and using an improved ultrafiltration method for measuring drug binding to BSA and to biological membranes, we found that the presence of BSA during the glucuronidation reaction leads to a large increase in the V(max) value of UGT1A9, in addition to lowering its K(m) value.	entacapone	43-53	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	79-85
21856742-3	2011	Nonetheless, using the specific substrates entacapone and zidovudine (AZT) for UGT1A9 and UGT2B7, respectively, and using an improved ultrafiltration method for measuring drug binding to BSA and to biological membranes, we found that the presence of BSA during the glucuronidation reaction leads to a large increase in the V(max) value of UGT1A9, in addition to lowering its K(m) value.	entacapone	43-53	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	90-96
21501335-1	2011	BACKGROUND: Entacapone is a promising drug used widely for the treatment of Parkinson"s disease (PD) as a catechol-O-methyl transferase (COMT) inhibitor.	entacapone	12-22	catechol-O-methyltransferase	Rattus norvegicus	106-135
21501335-1	2011	BACKGROUND: Entacapone is a promising drug used widely for the treatment of Parkinson"s disease (PD) as a catechol-O-methyl transferase (COMT) inhibitor.	entacapone	12-22	catechol-O-methyltransferase	Rattus norvegicus	137-141
21209248-4	2011	When luteolin was coadministered with a specific COMT inhibitor, entacapone, the formation of M1 and M2 was significantly reduced, whereas the plasma concentration of luteolin increased.	entacapone	65-75	catechol-O-methyltransferase	Rattus norvegicus	49-53
21280081-8	2011	Area under the concentration over time curve of levodopa increased more after entacapone in COMT(HH) than in COMT(LL) patients (+62 +- 6% vs +34 +- 8%, p = 0.01).	entacapone	78-88	catechol-O-methyltransferase	Homo sapiens	92-96
21280081-9	2011	COMT inhibition by entacapone was higher in COMT(HH) than in COMT(LL) patients (-0.54 +- 0.07 vs -0.31 +- 0.06 pmol/min/mg protein, p = 0.02).	entacapone	19-29	catechol-O-methyltransferase	Homo sapiens	0-4
21280081-9	2011	COMT inhibition by entacapone was higher in COMT(HH) than in COMT(LL) patients (-0.54 +- 0.07 vs -0.31 +- 0.06 pmol/min/mg protein, p = 0.02).	entacapone	19-29	catechol-O-methyltransferase	Homo sapiens	44-48
21280081-9	2011	COMT inhibition by entacapone was higher in COMT(HH) than in COMT(LL) patients (-0.54 +- 0.07 vs -0.31 +- 0.06 pmol/min/mg protein, p = 0.02).	entacapone	19-29	catechol-O-methyltransferase	Homo sapiens	44-48
21280081-10	2011	INTERPRETATION: The COMT(HH) genotype in PD patients enhances the effect of entacapone on the pharmacodynamics and pharmacokinetics of levodopa.	entacapone	76-86	catechol-O-methyltransferase	Homo sapiens	20-24
21164341-0	2011	Erythrocytes catechol-o-methyl transferase activity is up-regulated after a 3-month treatment by entacapone in parkinsonian patients.	entacapone	97-107	catechol-O-methyltransferase	Homo sapiens	13-42
21164341-1	2011	OBJECTIVES: Entacapone is a highly potent, reversible, peripherally acting catechol-O-methyl transferase (COMT) inhibitor that is used as an adjunct to L-dopa in the treatment of patients with Parkinson disease (PD).	entacapone	12-22	catechol-O-methyltransferase	Homo sapiens	75-104
21164341-1	2011	OBJECTIVES: Entacapone is a highly potent, reversible, peripherally acting catechol-O-methyl transferase (COMT) inhibitor that is used as an adjunct to L-dopa in the treatment of patients with Parkinson disease (PD).	entacapone	12-22	catechol-O-methyltransferase	Homo sapiens	106-110
21164341-2	2011	Nevertheless, the consequence of the long-lasting inhibition of COMT by entacapone has never been investigated.	entacapone	72-82	catechol-O-methyltransferase	Homo sapiens	64-68
21164341-3	2011	We assessed the variation of the soluble red blood cell (S-RBC)-COMT activity after 3 months of chronic treatment by entacapone.	entacapone	117-127	catechol-O-methyltransferase	Homo sapiens	64-68
21164341-9	2011	CONCLUSIONS: Our findings suggest that a long-lasting inhibition of the COMT may limit the efficacy of entacapone by development of a tolerance.	entacapone	103-113	catechol-O-methyltransferase	Homo sapiens	72-76
21524266-7	2011	Results from controlled human laboratory studies and small open-label clinical trials suggest that dronabinol, the COMT inhibitor entacapone, and lithium may warrant further study.	entacapone	130-140	catechol-O-methyltransferase	Homo sapiens	115-119
20464572-2	2010	The aim of this study was to assess plasma HCY levels in L-DOPA-treated Parkinson"s disease (PD) patients and its influence by adding the inhibitor COMT (entacapone).	entacapone	154-164	catechol-O-methyltransferase	Homo sapiens	148-152
21280081-0	2011	The COMT Val158Met polymorphism affects the response to entacapone in Parkinson"s disease: a randomized crossover clinical trial.	entacapone	56-66	catechol-O-methyltransferase	Homo sapiens	4-8
21280081-1	2011	OBJECTIVE: In Parkinson disease (PD), the selective C-O-methyltransferase (COMT) inhibitor entacapone prolongs the effect of levodopa on motor symptoms (ON time) by increasing its bioavailability.	entacapone	91-101	catechol-O-methyltransferase	Homo sapiens	52-73
20582993-2	2010	It has been hypothesized that providing more continuous delivery of L-dopa to the brain would reduce the risk of motor complications, and that this might be accomplished by combining L-dopa with entacapone, an inhibitor of catechol-O-methyltransferase, to extend its elimination half-life.	entacapone	195-205	catechol-O-methyltransferase	Homo sapiens	223-251
20856911-5	2010	In recent years, a new, safe, and efficacious armamentarium of treatment options has been provided by the marketing of the catechol-O-methyltransferase (COMT) inhibitor, entacapone, a peripheral blocker of dopa to 3-0-methyldopa metabolism, which increments levodopa brain availability.	entacapone	170-180	catechol-O-methyltransferase	Homo sapiens	123-151
20856911-5	2010	In recent years, a new, safe, and efficacious armamentarium of treatment options has been provided by the marketing of the catechol-O-methyltransferase (COMT) inhibitor, entacapone, a peripheral blocker of dopa to 3-0-methyldopa metabolism, which increments levodopa brain availability.	entacapone	170-180	catechol-O-methyltransferase	Homo sapiens	153-157
20572781-7	2010	The addition of the catechol-O-methyltransferase inhibitor entacapone (EN) to LD/carbidopa (CD) improves wearing off, as EN prolongs LD half-life and avoids troughs.	entacapone	59-69	catechol-O-methyltransferase	Homo sapiens	20-48
20572781-7	2010	The addition of the catechol-O-methyltransferase inhibitor entacapone (EN) to LD/carbidopa (CD) improves wearing off, as EN prolongs LD half-life and avoids troughs.	entacapone	71-73	catechol-O-methyltransferase	Homo sapiens	20-48
20694135-5	2010	Therefore, agents that prolong levodopa"s half-life were employed, such as carbidopa, an aromatic amino acid decarboxylase (AADC) inhibitor, and entacapone, a catechol-O-methyltransferase (COMT) inhibitor.	entacapone	145-155	catechol-O-methyltransferase	Homo sapiens	159-187
19629963-2	2010	Entacapone, a COMT inhibitor, prevented the formation of SAH only partially in the striatal homogenate whereas in the kidney homogenate the increase of SAH was prevented by entacapone.	entacapone	0-10	catechol-O-methyltransferase	Rattus norvegicus	14-18
20150427-0	2010	Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	30-58
20150427-0	2010	Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity.	entacapone	0-10	synuclein alpha	Homo sapiens	97-112
20150427-5	2010	Here, we show that entacapone and tolcapone are potent inhibitors of alpha-syn and beta-amyloid (Abeta) oligomerization and fibrillogenesis, and they also protect against extracellular toxicity induced by the aggregation of both proteins.	entacapone	19-29	synuclein alpha	Homo sapiens	69-78
20150427-5	2010	Here, we show that entacapone and tolcapone are potent inhibitors of alpha-syn and beta-amyloid (Abeta) oligomerization and fibrillogenesis, and they also protect against extracellular toxicity induced by the aggregation of both proteins.	entacapone	19-29	amyloid beta precursor protein	Homo sapiens	97-102
20150427-7	2010	Our findings present the first characterization of the anti-amyloidogenic properties of tolcapone and entacapone against both alpha-synuclein and Abeta42 and highlight the potential of this class of nitro-catechol compounds as anti-amyloidogenic agents.	entacapone	102-112	synuclein alpha	Homo sapiens	126-141
19629963-2	2010	Entacapone, a COMT inhibitor, prevented the formation of SAH only partially in the striatal homogenate whereas in the kidney homogenate the increase of SAH was prevented by entacapone.	entacapone	173-183	catechol-O-methyltransferase	Rattus norvegicus	14-18
20077469-2	2010	Adding the peripheral acting COMT inhibitor entacapone provides improvement for patients with PD suffering from motor fluctuations.	entacapone	44-54	catechol-O-methyltransferase	Homo sapiens	29-33
19909787-7	2010	Our results also support the conclusion that COMT inhibitors (entacapone or tolcapone), when administered in PD patients treated with l-Dopa, may potentiate the endogenous AdoHcy-dependent COMT inhibition mechanism already operative in a variable fashion.	entacapone	62-72	catechol-O-methyltransferase	Homo sapiens	45-49
19879254-0	2010	Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson"s disease induced by Japanese encephalitis virus.	entacapone	0-10	catechol-O-methyltransferase	Rattus norvegicus	14-42
19879254-5	2010	We analyzed the improvement in motor functions and catecholamine contents in various brain regions induced by a combination of the catechol-O-methyltransferase (COMT) inhibitor entacapone and a levodopa/dopadecarboxylase inhibitor (DDCI) in Japanese encephalitis virus (JEV) induced Parkinson"s disease model rats.	entacapone	177-187	catechol-O-methyltransferase	Rattus norvegicus	131-159
19909787-7	2010	Our results also support the conclusion that COMT inhibitors (entacapone or tolcapone), when administered in PD patients treated with l-Dopa, may potentiate the endogenous AdoHcy-dependent COMT inhibition mechanism already operative in a variable fashion.	entacapone	62-72	catechol-O-methyltransferase	Homo sapiens	189-193
19879254-5	2010	We analyzed the improvement in motor functions and catecholamine contents in various brain regions induced by a combination of the catechol-O-methyltransferase (COMT) inhibitor entacapone and a levodopa/dopadecarboxylase inhibitor (DDCI) in Japanese encephalitis virus (JEV) induced Parkinson"s disease model rats.	entacapone	177-187	catechol-O-methyltransferase	Homo sapiens	161-165
21095463-4	2010	One approach to the CDS is to prolong the half-life of L-dopa inhibiting its degradation by means of the administration of catechol-O-methyltransferase (COMT) inhibitors, as entacapone, a potent, selective, and reversible peripherally acting inhibitor.	entacapone	174-184	catechol-O-methyltransferase	Rattus norvegicus	123-151
21095464-1	2010	Entacapone and tolcapone are reversible COMT inhibitors which have been approved for clinical use in patients with Parkinson disease (PD).	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	40-44
19936145-4	2009	Recent LD trials indicate that a combination of LD with carbidopa (CD) and the catechol-O-methyltransferase (COMT) inhibitor entacapone (EN) may reduce the onset of these motor complications to a certain extent.	entacapone	125-135	catechol-O-methyltransferase	Homo sapiens	79-107
19783845-3	2010	Tolcapone and entacapone are potent inhibitors of catechol-O-methyltransferase (COMT) for the treatment of Parkinson"s disease.	entacapone	14-24	catechol-O-methyltransferase	Rattus norvegicus	50-78
19783845-3	2010	Tolcapone and entacapone are potent inhibitors of catechol-O-methyltransferase (COMT) for the treatment of Parkinson"s disease.	entacapone	14-24	catechol-O-methyltransferase	Rattus norvegicus	80-84
19936145-4	2009	Recent LD trials indicate that a combination of LD with carbidopa (CD) and the catechol-O-methyltransferase (COMT) inhibitor entacapone (EN) may reduce the onset of these motor complications to a certain extent.	entacapone	125-135	catechol-O-methyltransferase	Homo sapiens	109-113
19936145-4	2009	Recent LD trials indicate that a combination of LD with carbidopa (CD) and the catechol-O-methyltransferase (COMT) inhibitor entacapone (EN) may reduce the onset of these motor complications to a certain extent.	entacapone	137-139	catechol-O-methyltransferase	Homo sapiens	79-107
19936145-4	2009	Recent LD trials indicate that a combination of LD with carbidopa (CD) and the catechol-O-methyltransferase (COMT) inhibitor entacapone (EN) may reduce the onset of these motor complications to a certain extent.	entacapone	137-139	catechol-O-methyltransferase	Homo sapiens	109-113
19657587-2	2009	Aim was to investigate the impact of the peripheral COMT inhibitor entacapone (EN) on plasma concentrations of homocysteine, LD and 3-O-methyl-dopa (3-OMD).	entacapone	67-77	catechol-O-methyltransferase	Homo sapiens	52-56
19657587-2	2009	Aim was to investigate the impact of the peripheral COMT inhibitor entacapone (EN) on plasma concentrations of homocysteine, LD and 3-O-methyl-dopa (3-OMD).	entacapone	79-81	catechol-O-methyltransferase	Homo sapiens	52-56
19589043-8	2009	Stalevo is a combination tablet comprised of levodopa, carbidopa, and the COMT inhibitor entacapone.	entacapone	89-99	catechol-O-methyltransferase	Homo sapiens	74-78
19894644-3	2009	Furthermore, entacapone, a COMT inhibitor, is known to retain greater levodopa levels in plasma during coadministration.	entacapone	13-23	catechol-O-methyltransferase	Rattus norvegicus	27-31
19829918-5	2009	Levodopa/carbidopa/entacapone has been shown to improve the pharmacokinetic profile of levodopa and provide superior symptomatic control compared with conventional levodopa/dopa decarboxylase inhibitor therapy.	entacapone	19-29	dopa decarboxylase	Homo sapiens	173-191
19412946-1	2009	Controlled-release carbidopa and levodopa (CL-CR) and the combination of carbidopa, levodopa, and entacapone (CLE) are used for extending levodopa (L-dopa) effects.	entacapone	98-108	RNA transcription, translation and transport factor	Homo sapiens	110-113
18975095-2	2008	To some extent this is provided by Stalevo, which contains levodopa and two enzyme inhibitors: the DDC inhibitor carbidopa and the COMT inhibitor entacapone.	entacapone	146-156	catechol-O-methyltransferase	Homo sapiens	131-135
18691454-4	2009	Entacapone, a peripheral catechol-O-methyltransferase inhibitor has been shown to reduce OFF time and increase ON time in several therapeutic trials on PD patients treated with LD experiencing motor fluctuations.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	25-53
18520980-6	2008	The 3-OMD levels were significantly lower during catechol-O-methyltransferase (COMT) inhibition with entacapone.	entacapone	101-111	catechol-O-methyltransferase	Homo sapiens	49-77
19198095-3	2008	Good news were marketing of ropinirole, a new non-ergot agonist, in December 2006 and entacapone, the first catechol-O-methyl transferase (COMT) inhibitor in Japan in April 2007.	entacapone	86-96	catechol-O-methyltransferase	Homo sapiens	108-137
19198095-3	2008	Good news were marketing of ropinirole, a new non-ergot agonist, in December 2006 and entacapone, the first catechol-O-methyl transferase (COMT) inhibitor in Japan in April 2007.	entacapone	86-96	catechol-O-methyltransferase	Homo sapiens	139-143
18836344-1	2008	OBJECTIVE: The aim of the study was to explore the potential effect of the catechol-O-methyltransferase inhibitor entacapone coadministration on the rate of absorption and matched latency to motor response of an oral test dose of levodopa/benserazide in the treatment of Parkinson disease (PD).	entacapone	114-124	catechol-O-methyltransferase	Homo sapiens	75-103
18546331-1	2008	Entacapone (EN) improves the efficacy of levodopa/dopadecarboxylase inhibitor (LD/DDI) formulations by inhibition of the enzyme catechol-O-methyltransferase (COMT).	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	128-156
18546331-1	2008	Entacapone (EN) improves the efficacy of levodopa/dopadecarboxylase inhibitor (LD/DDI) formulations by inhibition of the enzyme catechol-O-methyltransferase (COMT).	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	158-162
18546331-1	2008	Entacapone (EN) improves the efficacy of levodopa/dopadecarboxylase inhibitor (LD/DDI) formulations by inhibition of the enzyme catechol-O-methyltransferase (COMT).	entacapone	12-14	catechol-O-methyltransferase	Homo sapiens	128-156
18546331-1	2008	Entacapone (EN) improves the efficacy of levodopa/dopadecarboxylase inhibitor (LD/DDI) formulations by inhibition of the enzyme catechol-O-methyltransferase (COMT).	entacapone	12-14	catechol-O-methyltransferase	Homo sapiens	158-162
18520980-6	2008	The 3-OMD levels were significantly lower during catechol-O-methyltransferase (COMT) inhibition with entacapone.	entacapone	101-111	catechol-O-methyltransferase	Homo sapiens	79-83
18290846-1	2008	Catechol-O-methyl transferase (COMT) inhibition by entacapone enhances levodopa absorption and reduces "off" time in Parkinson"s disease (PD).	entacapone	51-61	catechol-O-methyltransferase	Homo sapiens	0-29
18074122-7	2008	Furthermore, interfering in MDMA metabolism using the catechol-O-methyltransferase inhibitor entacapone potentiated the neurotoxicity of MDMA, indicating that metabolites that are substrates for this enzyme may contribute to neurotoxicity.	entacapone	93-103	catechol-O-methyltransferase	Rattus norvegicus	54-82
18290846-1	2008	Catechol-O-methyl transferase (COMT) inhibition by entacapone enhances levodopa absorption and reduces "off" time in Parkinson"s disease (PD).	entacapone	51-61	catechol-O-methyltransferase	Homo sapiens	31-35
18290846-6	2008	Bimodal entacapone increased COMT inhibition, improved the pharmacokinetics of levodopa and improved motor scores for 6 to 8 h. Bimodal use of entacapone may be useful in selected patients to improve motor control and implies that controlled release COMT inhibition would be beneficial in PD patients.	entacapone	8-18	catechol-O-methyltransferase	Homo sapiens	29-33
18290846-6	2008	Bimodal entacapone increased COMT inhibition, improved the pharmacokinetics of levodopa and improved motor scores for 6 to 8 h. Bimodal use of entacapone may be useful in selected patients to improve motor control and implies that controlled release COMT inhibition would be beneficial in PD patients.	entacapone	8-18	catechol-O-methyltransferase	Homo sapiens	250-254
18290846-6	2008	Bimodal entacapone increased COMT inhibition, improved the pharmacokinetics of levodopa and improved motor scores for 6 to 8 h. Bimodal use of entacapone may be useful in selected patients to improve motor control and implies that controlled release COMT inhibition would be beneficial in PD patients.	entacapone	143-153	catechol-O-methyltransferase	Homo sapiens	250-254
18052761-4	2007	Tolcapone and entacapone are selective and potent COMT inhibitors that slow the metabolism of levodopa, thus prolonging its effects.	entacapone	14-24	catechol-O-methyltransferase	Homo sapiens	50-54
18668620-2	2008	Recent studies have clearly demonstrated that the Off-related FOG is improved by levodopa (L-dopa) or entacapone treatment.	entacapone	102-112	zinc finger protein, FOG family member 1	Homo sapiens	62-65
17935716-1	2007	More continuous delivery of l-3,4-dihydroxyphenylalanine (l-dopa) achieved by combination with the catechol-O-methyl transfer (COMT) inhibitor entacapone reduces the onset of dyskinesia in MPTP-treated common marmosets compared with pulsatile l-dopa regimens.	entacapone	143-153	catechol O-methyltransferase	Callithrix jacchus	99-125
17935716-1	2007	More continuous delivery of l-3,4-dihydroxyphenylalanine (l-dopa) achieved by combination with the catechol-O-methyl transfer (COMT) inhibitor entacapone reduces the onset of dyskinesia in MPTP-treated common marmosets compared with pulsatile l-dopa regimens.	entacapone	143-153	catechol O-methyltransferase	Callithrix jacchus	127-131
17935716-7	2007	In contrast, the addition of l-dopa BID or QID with entacapone also produced some further improvement in motor function with the combination of entacapone and l-dopa BID significantly improving motor disability compared to l-dopa alone, but no further increase in dyskinesia intensity was observed compared with ropinirole alone treatment.	entacapone	52-62	BH3-interacting domain death agonist	Callithrix jacchus	166-169
17935716-7	2007	In contrast, the addition of l-dopa BID or QID with entacapone also produced some further improvement in motor function with the combination of entacapone and l-dopa BID significantly improving motor disability compared to l-dopa alone, but no further increase in dyskinesia intensity was observed compared with ropinirole alone treatment.	entacapone	144-154	BH3-interacting domain death agonist	Callithrix jacchus	36-39
17705259-6	2007	Therefore, the capacity of three catechol-O-methyltransferase (COMT) inhibitors, entacapone, nitecapone, and tolcapone to protect ALP from oxidative damage was also investigated and found to be very similar to the most potent reference antioxidants.	entacapone	81-91	alkaline phosphatase, placental	Homo sapiens	130-133
17408604-9	2007	On the other hand entacapone, a catechol-O-methyl transferase (COMT) inhibitor, only increased the cytotoxicity of 3",4"-diCl-3,4-diOH-biphenyl, 3",4"-diCl-2,3-diOH-biphenyl and 4"-Cl-2,3-diOH-biphenyl.	entacapone	18-28	catechol-O-methyltransferase	Rattus norvegicus	32-61
17408604-9	2007	On the other hand entacapone, a catechol-O-methyl transferase (COMT) inhibitor, only increased the cytotoxicity of 3",4"-diCl-3,4-diOH-biphenyl, 3",4"-diCl-2,3-diOH-biphenyl and 4"-Cl-2,3-diOH-biphenyl.	entacapone	18-28	catechol-O-methyltransferase	Rattus norvegicus	63-67
17495756-6	2007	In addition, preclinical studies suggest that adjunctive use of the catechol-O-methyltransferase (COMT) inhibitor entacapone when levodopa is first introduced may be associated with fewer motor complications than treatment with levodopa alone.	entacapone	114-124	catechol-O-methyltransferase	Homo sapiens	68-96
17495756-6	2007	In addition, preclinical studies suggest that adjunctive use of the catechol-O-methyltransferase (COMT) inhibitor entacapone when levodopa is first introduced may be associated with fewer motor complications than treatment with levodopa alone.	entacapone	114-124	catechol-O-methyltransferase	Homo sapiens	98-102
16906435-4	2007	1-Naphthol (hUGT1A6), 1-hydroxypyrene (hUGT1A6/1A9), and entacapone (hUGT1A9) are markers of PAH-glucuronidating human uridine diphosphate-glucuronosyltransferases (UGT).	entacapone	57-67	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	69-76
17630819-11	2007	Therefore, agents that block COMT, such as tolcapone and entacapone, increase the elimination half-life of levodopa.	entacapone	57-67	catechol-O-methyltransferase	Homo sapiens	29-33
16604302-1	2006	Addition of the catechol-O-methyltransferase (COMT) inhibitor entacapone (EN) prolongs plasma metabolism of levodopa (LD).	entacapone	74-76	catechol-O-methyltransferase	Homo sapiens	16-44
16604302-1	2006	Addition of the catechol-O-methyltransferase (COMT) inhibitor entacapone (EN) prolongs plasma metabolism of levodopa (LD).	entacapone	74-76	catechol-O-methyltransferase	Homo sapiens	46-50
16026927-7	2005	The ischemia-induced dialysate catecholamines levels were compared with and without the pretreatment with entacapone (COMT inhibitor, 10 mg/kg, i.p.).	entacapone	106-116	catechol O-methyltransferase	Oryctolagus cuniculus	118-122
16604302-1	2006	Addition of the catechol-O-methyltransferase (COMT) inhibitor entacapone (EN) prolongs plasma metabolism of levodopa (LD).	entacapone	62-72	catechol-O-methyltransferase	Homo sapiens	16-44
16604302-1	2006	Addition of the catechol-O-methyltransferase (COMT) inhibitor entacapone (EN) prolongs plasma metabolism of levodopa (LD).	entacapone	62-72	catechol-O-methyltransferase	Homo sapiens	46-50
17948613-7	2006	Catechol-O-methyltransferase (COMT)inhibitors, which increase dopamine levels by inhibiting the metabolism of levodopa and dopamine, recently have become available, including a tablet containing carbidopa, levodopa,and entacapone.	entacapone	219-229	catechol-O-methyltransferase	Homo sapiens	0-28
17948613-7	2006	Catechol-O-methyltransferase (COMT)inhibitors, which increase dopamine levels by inhibiting the metabolism of levodopa and dopamine, recently have become available, including a tablet containing carbidopa, levodopa,and entacapone.	entacapone	219-229	catechol-O-methyltransferase	Homo sapiens	30-34
16437585-4	2006	Inhibition of the enzyme catechol-O-methyl transferase (COMT) by entacapone extends the half-life of levodopa and minimizes variability in plasma levodopa levels.	entacapone	65-75	catechol-O-methyltransferase	Rattus norvegicus	25-54
16437585-4	2006	Inhibition of the enzyme catechol-O-methyl transferase (COMT) by entacapone extends the half-life of levodopa and minimizes variability in plasma levodopa levels.	entacapone	65-75	catechol-O-methyltransferase	Rattus norvegicus	56-60
16437585-5	2006	The aim of the present study was to characterize the effect of the early administration of the COMT inhibitor entacapone in the recently described model of LIDs in rats with a nigrostriatal lesion induced by 6-hydroxydopamine (6-OHDA).	entacapone	110-120	catechol-O-methyltransferase	Rattus norvegicus	95-99
16614536-1	2006	Adjunction of the catechol-O-methyltransferase (COMT) inhibitor entacapone (EN) to levodopa/carbidopa (LD/CD) improves motor symptoms in patients with Parkinson disease (PD) by a prolonged elimination of LD.	entacapone	64-74	catechol-O-methyltransferase	Homo sapiens	18-46
16614536-1	2006	Adjunction of the catechol-O-methyltransferase (COMT) inhibitor entacapone (EN) to levodopa/carbidopa (LD/CD) improves motor symptoms in patients with Parkinson disease (PD) by a prolonged elimination of LD.	entacapone	64-74	catechol-O-methyltransferase	Homo sapiens	48-52
16614536-1	2006	Adjunction of the catechol-O-methyltransferase (COMT) inhibitor entacapone (EN) to levodopa/carbidopa (LD/CD) improves motor symptoms in patients with Parkinson disease (PD) by a prolonged elimination of LD.	entacapone	76-78	catechol-O-methyltransferase	Homo sapiens	18-46
16614536-1	2006	Adjunction of the catechol-O-methyltransferase (COMT) inhibitor entacapone (EN) to levodopa/carbidopa (LD/CD) improves motor symptoms in patients with Parkinson disease (PD) by a prolonged elimination of LD.	entacapone	76-78	catechol-O-methyltransferase	Homo sapiens	48-52
16211593-2	2006	Administration of LD/CD with the catechol-O-methyltransferase inhibitor entacapone in one tablet (LCE) may extend plasma half-life of LD and thus its effect on motor symptoms in patients with Parkinson"s disease (PD).	entacapone	72-82	catechol-O-methyltransferase	Homo sapiens	33-61
16026927-10	2005	Inhibition of COMT activity by entacapone augmented the ischemia-induced NE levels (54,306+/-6618 pg/ml), EPI levels (2681+/-567 pg/ml), and DA (3551+/-710 pg/ml) levels at the last 15 min of coronary occlusion.	entacapone	31-41	catechol O-methyltransferase	Oryctolagus cuniculus	14-18
15802387-3	2005	The glucuronidation of entacapone by UGT1A9 was inhibited by 1-naphthol in a competitive fashion, with respect to entacapone, and an uncompetitive fashion, with respect to UDP-glucuronic acid (UDPGA).	entacapone	23-33	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	37-43
15614425-0	2005	The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats.	entacapone	20-30	catechol-O-methyltransferase	Rattus norvegicus	4-8
15614425-3	2005	In this study, the effects of the COMT inhibitor, entacapone, on levodopa-induced hyperhomocysteinaemia were studied in rats.	entacapone	50-60	catechol-O-methyltransferase	Rattus norvegicus	34-38
15802387-3	2005	The glucuronidation of entacapone by UGT1A9 was inhibited by 1-naphthol in a competitive fashion, with respect to entacapone, and an uncompetitive fashion, with respect to UDP-glucuronic acid (UDPGA).	entacapone	114-124	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	37-43
15802387-7	2005	Relative specificity constants were calculated for the eight UGT1A isoforms with 1-hydroxypyrene, 4-nitrophenol, scopoletin, 4-methylumbelliferone, and entacapone as aglycone substrates.	entacapone	152-162	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	61-66
15779086-5	2005	tHcy export from astrocytes was also induced by the COMT substrates levodopa (L-DOPA), dopamine and quercetin, and it was blocked by the COMT inhibitors tropolone and entacapone.	entacapone	167-177	catechol-O-methyltransferase	Homo sapiens	137-141
15907741-4	2005	Randomised, controlled trials have shown that in patients with PD who have motor fluctuations, the addition of the COMT-inhibitor entacapone results in an improvement in motor fluctuations, particularly of the "wearing-off" type, with about 1.0-1.7 h more on-time and less off-time per day, reduced required levodopa dose, modest improvement in motor and disability scores (mean total unified PD rating scale [UPDRS] scores of about 4.5), and in some but not all studies improvement of health-related quality of life [HRQOL] scores.	entacapone	130-140	catechol-O-methyltransferase	Homo sapiens	115-119
15907741-5	2005	RECENT DEVELOPMENTS: Patients with stable PD, without motor fluctuations, also have improved HRQOL scores on treatment with entacapone in addition to levodopa with a dopa-decarboxylase inhibitor.	entacapone	124-134	dopa decarboxylase	Homo sapiens	166-184
15878587-4	2005	The objective of our study was to assess the impact of entacapone, a COMT inhibitor, on plasma levels of homocysteine, serum folate, and vitamin B12 in levodopa-treated PD patients.	entacapone	55-65	catechol-O-methyltransferase	Homo sapiens	69-73
15965309-1	2005	Entacapone is a catechol-O-methyltransferase (COMT) inhibitor used as an adjunct to levodopa/dopa decarboxylase inhibitors in the treatment of Parkinson"s disease.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	16-44
15965309-1	2005	Entacapone is a catechol-O-methyltransferase (COMT) inhibitor used as an adjunct to levodopa/dopa decarboxylase inhibitors in the treatment of Parkinson"s disease.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	46-50
15965309-1	2005	Entacapone is a catechol-O-methyltransferase (COMT) inhibitor used as an adjunct to levodopa/dopa decarboxylase inhibitors in the treatment of Parkinson"s disease.	entacapone	0-10	dopa decarboxylase	Homo sapiens	93-111
15965309-9	2005	Entacapone significantly reduced plasma 3-OMD concentration by about 50% (P = 0.0001), indicating marked COMT inhibiting activity.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	105-109
15613619-8	2005	In contrast, l-DOPA or the dopamine-metabolizing enzyme inhibitor entacapone suppressed low-salt-induced cortical COX-2 expression.	entacapone	66-76	prostaglandin-endoperoxide synthase 2	Homo sapiens	114-119
15503197-4	2005	Catechol-O-methyltransferase (COMT) inhibitors such as entacapone extend the plasma half-life of levodopa and reduce "off" time.	entacapone	55-65	catechol-O-methyltransferase	Homo sapiens	0-28
15784340-1	2005	Aqueous solubility, apparent partition coefficient (logPapp) and catechol-O-methyltransferase (COMT, EC 2.1.1.6) inhibiting potency of entacapone and tolcapone were compared in vitro.	entacapone	135-145	catechol-O-methyltransferase	Rattus norvegicus	65-93
15784340-1	2005	Aqueous solubility, apparent partition coefficient (logPapp) and catechol-O-methyltransferase (COMT, EC 2.1.1.6) inhibiting potency of entacapone and tolcapone were compared in vitro.	entacapone	135-145	catechol-O-methyltransferase	Rattus norvegicus	95-99
15784340-6	2005	Entacapone and tolcapone inhibited equally rat striatal COMT in vitro with Ki values of 1.86 and 2.50 nM, respectively.	entacapone	0-10	catechol-O-methyltransferase	Rattus norvegicus	56-60
15784340-10	2005	In conclusion, entacapone and tolcapone are equally potent COMT inhibitors against rat striatal COMT in vitro.	entacapone	15-25	catechol-O-methyltransferase	Rattus norvegicus	59-63
15784340-10	2005	In conclusion, entacapone and tolcapone are equally potent COMT inhibitors against rat striatal COMT in vitro.	entacapone	15-25	catechol-O-methyltransferase	Rattus norvegicus	96-100
15784340-11	2005	After local intrastriatal administration, entacapone appeared to inhibit COMT faster and more effectively than the more lipophilic tolcapone.	entacapone	42-52	catechol-O-methyltransferase	Rattus norvegicus	73-77
15698633-1	2005	The purpose of this study was to investigate the effect of the catechol-O-methyltransferase (COMT) inhibitor, entacapone, in the reversal and prevention of "wearing-off" phenomena in hemiparkinsonian rats.	entacapone	110-120	catechol-O-methyltransferase	Rattus norvegicus	63-91
15698633-1	2005	The purpose of this study was to investigate the effect of the catechol-O-methyltransferase (COMT) inhibitor, entacapone, in the reversal and prevention of "wearing-off" phenomena in hemiparkinsonian rats.	entacapone	110-120	catechol-O-methyltransferase	Rattus norvegicus	93-97
15503197-4	2005	Catechol-O-methyltransferase (COMT) inhibitors such as entacapone extend the plasma half-life of levodopa and reduce "off" time.	entacapone	55-65	catechol-O-methyltransferase	Homo sapiens	30-34
15548391-2	2004	Surprisingly, the corresponding mutation in UGT1A9 (Y483D) doubled the Vmax of scopoletin glucuronidation, whereas the entacapone glucuronidation rate was decreased by about 50%.	entacapone	119-129	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	44-50
15548391-7	2004	The UGT1A4 was selected because it glucuronidates neither entacapone nor scopoletin at significant rates.	entacapone	58-68	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	4-10
15548391-8	2004	The active enzyme in these hetero-dimers was 1A9Sol, a truncation mutant of UGT1A9 that exhibited a very low ratio of entacapone to scopoletin glucuronidation rates.	entacapone	118-128	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	76-82
15548391-9	2004	Interestingly, the ratio of entacapone to scopoletin glucuronidation rates in the co-infected cells was dependent on, and markedly increased with, the probability that 1A9Sol forms hetero-dimers with UGT1A4.	entacapone	28-38	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	200-206
15548391-10	2004	In addition, the apparent Km for entacapone in the hetero-dimers was much lower than in 1A9Sol, and resembled the corresponding value in full-length UGT1A9.	entacapone	33-43	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	149-155
15379738-1	2004	BACKGROUND: Entacapone is a COMT inhibitor used in Parkinson"s disease (PD) patients, as an adjunctive therapy to L-dopa in order to prolong its bioavailability and thus its clinical effect.	entacapone	12-22	catechol-O-methyltransferase	Homo sapiens	28-32
15502970-2	2004	This study was aimed at investigating the effect of adding the catechol- O-methyltransferase (COMT) inhibitor entacapone to chronic treatment with l-DOPA/benserazide.	entacapone	110-120	catechol-O-methyltransferase	Rattus norvegicus	63-92
15502970-2	2004	This study was aimed at investigating the effect of adding the catechol- O-methyltransferase (COMT) inhibitor entacapone to chronic treatment with l-DOPA/benserazide.	entacapone	110-120	catechol-O-methyltransferase	Rattus norvegicus	94-98
15477510-1	2004	BACKGROUND: The catechol O-methyltransferase inhibitor entacapone acts by extending the elimination half-life of levodopa and is currently approved as an adjunct to levodopa for the treatment of patients with Parkinson disease (PD) with motor fluctuations.	entacapone	55-65	catechol-O-methyltransferase	Homo sapiens	16-44
15477510-11	2004	CONCLUSIONS: The catechol O-methyltransferase inhibitor entacapone, used as an adjunct to levodopa in PD patients who do not experience motor fluctuations, does not improve Unified Parkinson"s Disease Rating Scale motor scores but does improve a variety of quality-of-life measures.	entacapone	56-66	catechol-O-methyltransferase	Homo sapiens	17-45
15364620-7	2004	RESULTS: In control, entacapone increased interstitial dihydroxyphenylglycol (DHPG, intraneuronal NE metabolite by monoamine oxidase (MAO)) levels and decreased interstitial normetanephrine (NMN, extraneuronal NE metabolite by COMT) and 3-methoxy-4-hydroxyphenylglycol (MHPG, extraneuronal DHPG metabolite by COMT) levels, but did not change interstitial NE levels.	entacapone	21-31	catechol O-methyltransferase	Oryctolagus cuniculus	227-231
15364620-7	2004	RESULTS: In control, entacapone increased interstitial dihydroxyphenylglycol (DHPG, intraneuronal NE metabolite by monoamine oxidase (MAO)) levels and decreased interstitial normetanephrine (NMN, extraneuronal NE metabolite by COMT) and 3-methoxy-4-hydroxyphenylglycol (MHPG, extraneuronal DHPG metabolite by COMT) levels, but did not change interstitial NE levels.	entacapone	21-31	catechol O-methyltransferase	Oryctolagus cuniculus	309-313
15340869-0	2004	Clinical advantages of COMT inhibition with entacapone - a review.	entacapone	44-54	catechol-O-methyltransferase	Homo sapiens	23-27
15340869-1	2004	Two catechol- O-methyltransferase (COMT) inhibitors, entacapone and tolcapone, were developed during the 1990"s to be used as adjuncts to levodopa (LD) - dopa decarboxylase (DDC) inhibitors in the treatment of Parkinson"s disease (PD).	entacapone	53-63	catechol-O-methyltransferase	Homo sapiens	4-33
15340869-1	2004	Two catechol- O-methyltransferase (COMT) inhibitors, entacapone and tolcapone, were developed during the 1990"s to be used as adjuncts to levodopa (LD) - dopa decarboxylase (DDC) inhibitors in the treatment of Parkinson"s disease (PD).	entacapone	53-63	catechol-O-methyltransferase	Homo sapiens	35-39
14975680-1	2004	Tolcapone and entacapone are catechol-O-methyltransferase (COMT) inhibitors used as adjuncts to levodopa in the treatment of Parkinson"s disease (PD).	entacapone	14-24	catechol-O-methyltransferase	Homo sapiens	29-57
15372589-1	2004	We investigated whether administration of the catechol-O-methyl transferase (COMT) inhibitor entacapone, at doses of 200 mg and 400 mg, alters the pharmacokinetics of apomorphine in Parkinson"s disease patients experiencing severe motor fluctuations.	entacapone	93-103	catechol-O-methyltransferase	Homo sapiens	46-75
15372589-1	2004	We investigated whether administration of the catechol-O-methyl transferase (COMT) inhibitor entacapone, at doses of 200 mg and 400 mg, alters the pharmacokinetics of apomorphine in Parkinson"s disease patients experiencing severe motor fluctuations.	entacapone	93-103	catechol-O-methyltransferase	Homo sapiens	77-81
15221622-1	2004	Entacapone is a specific, peripherally acting catechol- O-methyltransferase (COMT) inhibitor that prevents peripheral degradation of L-dopa, thus improving its bioavailability.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	46-75
15221622-1	2004	Entacapone is a specific, peripherally acting catechol- O-methyltransferase (COMT) inhibitor that prevents peripheral degradation of L-dopa, thus improving its bioavailability.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	77-81
15182744-3	2004	Administration of COMT inhibitor (entacapone) decreased dialysate 3-methoxy 4-hydroxyphenylglycol (MHPG) levels.	entacapone	34-44	catechol O-methyltransferase	Oryctolagus cuniculus	18-22
15044611-7	2004	UGT1A9Sol exhibited a relatively high rate of scopoletin glucuronidation, whereas its activity toward 1-naphthol, entacapone, umbelliferone, and 4-nitrophenol was much lower.	entacapone	114-124	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	0-6
14975680-1	2004	Tolcapone and entacapone are catechol-O-methyltransferase (COMT) inhibitors used as adjuncts to levodopa in the treatment of Parkinson"s disease (PD).	entacapone	14-24	catechol-O-methyltransferase	Homo sapiens	59-63
14767720-1	2004	The aim of this trial was to evaluate the effects of the COMT inhibitor entacapone on both the pharmacokinetic profile and clinical efficacy of controlled release levodopa in Parkinson"s disease (PD) patients.	entacapone	72-82	catechol-O-methyltransferase	Homo sapiens	57-61
14718678-1	2004	Several prospective double-blind, placebo-controlled trials have demonstrated that combining levodopa with the COMT inhibitor entacapone is efficacious in reducing motor fluctuations.	entacapone	126-136	catechol-O-methyltransferase	Homo sapiens	111-115
14718679-1	2004	Combining levodopa with the catechol-O-methyltransferase (COMT) inhibitor entacapone has been shown to be an effective strategy in the management of Parkinson"s disease (PD) patients experiencing motor fluctuations.	entacapone	74-84	catechol-O-methyltransferase	Homo sapiens	28-56
14718679-1	2004	Combining levodopa with the catechol-O-methyltransferase (COMT) inhibitor entacapone has been shown to be an effective strategy in the management of Parkinson"s disease (PD) patients experiencing motor fluctuations.	entacapone	74-84	catechol-O-methyltransferase	Homo sapiens	58-62
14718680-6	2004	In MPTP monkeys, administration of multiple small doses of levodopa in conjunction with the peripheral COMT inhibitor entacapone removes much of the pulsatility of motor function seen with standard levodopa treatment regimens and, at the same time, results in a lower incidence and intensity of dyskinesia.	entacapone	118-128	catechol-O-methyltransferase	Homo sapiens	103-107
14741081-1	2004	The catechol-O-methyl transferase inhibitor entacapone is given in combination with levodopa/dopa decarboxylase inhibitor for Parkinson"s disease (PD) patients experiencing end-of-dose wearing-off.	entacapone	44-54	catechol-O-methyltransferase	Homo sapiens	4-33
15124929-9	2003	Our models propose that increasing steric volume of e.g. the diethylamine tail of entacapone is favourable for COMT inhibitory activity.	entacapone	82-92	catechol-O-methyltransferase	Homo sapiens	111-115
14630372-4	2003	The MHPG concentrations were reduced by entacapone (catechol-O-methyltransferase inhibitor, COMT), augmented by local infusion of dihydroxyphenylglycol.	entacapone	40-50	catechol O-methyltransferase	Oryctolagus cuniculus	52-80
14654757-0	2003	Entacapone protects from angiotensin II-induced inflammation and renal injury.	entacapone	0-10	angiotensinogen	Rattus norvegicus	25-39
14654757-2	2003	We tested the hypothesis whether entacapone, a catechol-O-methyltransferase (COMT) inhibitor exerting antioxidative and anti-inflammatory properties, protects against the Ang II-induced inflammatory response and end-organ damage.	entacapone	33-43	catechol-O-methyltransferase	Rattus norvegicus	47-75
14654757-2	2003	We tested the hypothesis whether entacapone, a catechol-O-methyltransferase (COMT) inhibitor exerting antioxidative and anti-inflammatory properties, protects against the Ang II-induced inflammatory response and end-organ damage.	entacapone	33-43	catechol-O-methyltransferase	Rattus norvegicus	77-81
14654757-2	2003	We tested the hypothesis whether entacapone, a catechol-O-methyltransferase (COMT) inhibitor exerting antioxidative and anti-inflammatory properties, protects against the Ang II-induced inflammatory response and end-organ damage.	entacapone	33-43	angiotensinogen	Rattus norvegicus	171-177
14654757-6	2003	Entacapone ameliorated Ang II-induced vascular and glomerular damage, leucocyte infiltration, and intercellular adhesion molecule-1 (ICAM-1) overexpression in the kidneys.	entacapone	0-10	angiotensinogen	Rattus norvegicus	23-29
14654757-6	2003	Entacapone ameliorated Ang II-induced vascular and glomerular damage, leucocyte infiltration, and intercellular adhesion molecule-1 (ICAM-1) overexpression in the kidneys.	entacapone	0-10	intercellular adhesion molecule 1	Rattus norvegicus	98-131
14654757-6	2003	Entacapone ameliorated Ang II-induced vascular and glomerular damage, leucocyte infiltration, and intercellular adhesion molecule-1 (ICAM-1) overexpression in the kidneys.	entacapone	0-10	intercellular adhesion molecule 1	Rattus norvegicus	133-139
14654757-8	2003	Entacapone also decreased p22phox mRNA expression in the kidney.	entacapone	0-10	cytochrome b-245 alpha chain	Rattus norvegicus	26-33
14654757-11	2003	Even though entacapone decreased renal COMT activity by 40%, the renal dopaminergic tone remained unchanged in entacapone-treated dTGR.	entacapone	12-22	catechol-O-methyltransferase	Rattus norvegicus	39-43
14654757-12	2003	CONCLUSION: Our findings suggest that entacapone provides protection against Ang II-induced renal damage through antioxidative and anti-inflammatory mechanisms, rather than by COMT inhibition-induced changes in renal dopaminergic tone.	entacapone	38-48	angiotensinogen	Rattus norvegicus	77-83
12876237-1	2003	OBJECTIVE: To study the effect of entacapone, a specific peripherally acting catechol-O-methyltransferase (COMT) inhibitor used in combination with levodopa treatment, in cases of Parkinson"s disease with both fluctuating and non-fluctuating response to treatment.	entacapone	34-44	catechol-O-methyltransferase	Homo sapiens	77-105
12876237-10	2003	In this group of patients, ADL scores improved in the entacapone group (p < 0.01 v placebo), and there was also a 40 mg reduction in levodopa requirement (p < 0.01 v placebo).	entacapone	54-64	sarcoglycan alpha	Homo sapiens	27-30
12876237-13	2003	A novel finding was that patients without fluctuations also obtained benefit from the addition of entacapone to their levodopa treatment, as evidenced by improved ADL scores and a relatively reduced levodopa requirement.	entacapone	98-108	sarcoglycan alpha	Homo sapiens	163-166
12876237-1	2003	OBJECTIVE: To study the effect of entacapone, a specific peripherally acting catechol-O-methyltransferase (COMT) inhibitor used in combination with levodopa treatment, in cases of Parkinson"s disease with both fluctuating and non-fluctuating response to treatment.	entacapone	34-44	catechol-O-methyltransferase	Homo sapiens	107-111
12603288-1	2003	The long-term safety and efficacy of the catechol-O-methyltransferase (COMT) inhibitor entacapone was investigated in a 3-year open-label extension of the 6-month double-blind placebo-controlled Nordic (NOMECOMT) study.	entacapone	87-97	catechol-O-methyltransferase	Homo sapiens	41-69
12904105-1	2003	Entacapone and tolcapone are selective catechol-O-methyltransferase (COMT) inhibitors developed recently as adjuncts to levodopa for the treatment of Parkinson"s disease (PD).	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	39-67
12904105-1	2003	Entacapone and tolcapone are selective catechol-O-methyltransferase (COMT) inhibitors developed recently as adjuncts to levodopa for the treatment of Parkinson"s disease (PD).	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	69-73
12603288-1	2003	The long-term safety and efficacy of the catechol-O-methyltransferase (COMT) inhibitor entacapone was investigated in a 3-year open-label extension of the 6-month double-blind placebo-controlled Nordic (NOMECOMT) study.	entacapone	87-97	catechol-O-methyltransferase	Homo sapiens	71-75
12952501-1	2003	Entacapone (Comtess/Comtan) is Orion Pharma"s original proprietary catechol-O-methyl transferase (COMT) inhibitor.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	67-96
12588639-0	2003	Sleep attacks in Parkinson"s disease induced by Entacapone, a COMT-inhibitor.	entacapone	48-58	catechol-O-methyltransferase	Homo sapiens	62-66
12538800-1	2003	Two catechol-O-methyltransferase (COMT) inhibitors, entacapone and tolcapone, were compared in the rat to elucidate the actual differences between their pharmacokinetics and pharmacodynamics after single and repeated administration.	entacapone	52-62	catechol-O-methyltransferase	Rattus norvegicus	34-38
12538800-5	2003	After a single oral dose (10 mg/kg), both entacapone and tolcapone produced an equal maximal degree of COMT inhibition in peripheral tissues, but tolcapone inhibited striatal COMT more effectively than did entacapone.	entacapone	42-52	catechol-O-methyltransferase	Rattus norvegicus	103-107
12538800-5	2003	After a single oral dose (10 mg/kg), both entacapone and tolcapone produced an equal maximal degree of COMT inhibition in peripheral tissues, but tolcapone inhibited striatal COMT more effectively than did entacapone.	entacapone	42-52	catechol-O-methyltransferase	Rattus norvegicus	175-179
12538800-6	2003	After the 7-day treatment (10 mg/kg twice daily), COMT activity had recovered to a level of 67 to 101% of control within 8 h after the last dose of entacapone.	entacapone	148-158	catechol-O-methyltransferase	Rattus norvegicus	50-54
12538800-8	2003	The pharmacokinetic-pharmacodynamic modeling revealed that a plateau of COMT inhibition near the maximal attainable inhibition was reached already by plasma concentrations below 2000 ng/ml, both with entacapone and tolcapone.	entacapone	200-210	catechol-O-methyltransferase	Rattus norvegicus	72-76
12538800-9	2003	Entacapone and tolcapone inhibited equally rat liver COMT in vitro with K(i) values of 10.7 and 10.0 nM, respectively.	entacapone	0-10	catechol-O-methyltransferase	Rattus norvegicus	53-57
12952501-1	2003	Entacapone (Comtess/Comtan) is Orion Pharma"s original proprietary catechol-O-methyl transferase (COMT) inhibitor.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	98-102
12573869-1	2003	Tolcapone is a mixed (peripheral and central) catechol-O-methyltransferase (COMT) inhibitor, whereas entacapone is a preferential peripheral COMT inhibitor.	entacapone	101-111	catechol-O-methyltransferase	Rattus norvegicus	141-145
12573869-5	2003	Tolcapone and entacapone, at the dose of 15 mg/kg p.o., were almost equally effective in inhibiting COMT activity in duodenum and liver.	entacapone	14-24	catechol-O-methyltransferase	Rattus norvegicus	100-104
12393055-1	2002	Catechol-O-methyl transferase (COMT) inhibitors, entacapone and tolcapone, are used as an adjunctive treatment to L-dopa in Parkinson"s disease.	entacapone	49-59	catechol-O-methyltransferase	Rattus norvegicus	31-35
12454735-1	2002	The toxicity profiles of entacapone and tolcapone, novel catechol- O-methyl-transferase (COMT) inhibitors, have been reported to differ from each other.	entacapone	25-35	catechol-O-methyltransferase	Rattus norvegicus	57-87
12454735-1	2002	The toxicity profiles of entacapone and tolcapone, novel catechol- O-methyl-transferase (COMT) inhibitors, have been reported to differ from each other.	entacapone	25-35	catechol-O-methyltransferase	Rattus norvegicus	89-93
12392583-1	2002	AIMS: Entacapone is a peripherally acting catechol-O-methyltransferase (COMT) inhibitor.	entacapone	6-16	catechol-O-methyltransferase	Homo sapiens	42-70
12392583-1	2002	AIMS: Entacapone is a peripherally acting catechol-O-methyltransferase (COMT) inhibitor.	entacapone	6-16	catechol-O-methyltransferase	Homo sapiens	72-76
12393055-6	2002	The COMT inhibitory activity of entacapone was reduced to half, while tolcapone had only about 1/10 of its activity left in the presence of serum.	entacapone	32-42	catechol-O-methyltransferase	Rattus norvegicus	4-8
12111468-0	2002	Different modes of action of catecholamine-O-methyltransferase inhibitors entacapone and tolcapone on adenylyl cyclase activity in vitro.	entacapone	74-84	catechol-O-methyltransferase	Rattus norvegicus	29-62
12135946-2	2002	METHODS AND RESULTS: We studied incremental doses of the COMT inhibitor entacapone, the sympathetic stimulant yohimbine, and placebo in 7 patients with multiple system atrophy (Shy Drager syndrome).	entacapone	72-82	catechol-O-methyltransferase	Homo sapiens	57-61
12083995-1	2002	Entacapone is one of a new class of drugs, the catechol-O-methyltransferase (COMT) inhibitors, which expand the therapeutic options for Parkinson"s disease by extending the action of levodopa.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	47-75
12083995-1	2002	Entacapone is one of a new class of drugs, the catechol-O-methyltransferase (COMT) inhibitors, which expand the therapeutic options for Parkinson"s disease by extending the action of levodopa.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	77-81
12180806-1	2002	Entacapone and tolcapone, novel catechol-O-methyl-transferase (COMT) inhibitors, have been developed for the treatment of Parkinson"s disease in combination with levodopa.	entacapone	0-10	catechol-O-methyltransferase	Rattus norvegicus	32-61
12180806-1	2002	Entacapone and tolcapone, novel catechol-O-methyl-transferase (COMT) inhibitors, have been developed for the treatment of Parkinson"s disease in combination with levodopa.	entacapone	0-10	catechol-O-methyltransferase	Rattus norvegicus	63-67
12403054-1	2002	The aim of this in vivo study was to assess the effect of improved oral bioavailability of entacapone on its actual pharmacodynamic response, COMT inhibition in erythrocytes.	entacapone	91-101	catechol-O-methyltransferase	Rattus norvegicus	142-146
12403054-4	2002	The administration of entacapone as a solution (plain solution pH 7.4; F=34.8% or entacapone/HP-beta-CD solution pH 3.0; F = 18.5%) resulted in significantly higher degree of COMT inhibition in erythrocytes than could be achieved by administering entacapone as a suspension (pH 3.0; F=8.9%).	entacapone	22-32	catechol-O-methyltransferase	Rattus norvegicus	175-179
12403054-4	2002	The administration of entacapone as a solution (plain solution pH 7.4; F=34.8% or entacapone/HP-beta-CD solution pH 3.0; F = 18.5%) resulted in significantly higher degree of COMT inhibition in erythrocytes than could be achieved by administering entacapone as a suspension (pH 3.0; F=8.9%).	entacapone	82-92	catechol-O-methyltransferase	Rattus norvegicus	175-179
12403054-4	2002	The administration of entacapone as a solution (plain solution pH 7.4; F=34.8% or entacapone/HP-beta-CD solution pH 3.0; F = 18.5%) resulted in significantly higher degree of COMT inhibition in erythrocytes than could be achieved by administering entacapone as a suspension (pH 3.0; F=8.9%).	entacapone	82-92	catechol-O-methyltransferase	Rattus norvegicus	175-179
12111468-1	2002	Catechol-O-methyltransferase (COMT) inhibitors such as entacapone and tolcapone are used as adjuncts to L-DOPA ( l-3,4-dihydroxyphenylalanine, levodopa) in the treatment of Parkinson"s disease.	entacapone	55-65	catechol-O-methyltransferase	Rattus norvegicus	0-28
12111468-1	2002	Catechol-O-methyltransferase (COMT) inhibitors such as entacapone and tolcapone are used as adjuncts to L-DOPA ( l-3,4-dihydroxyphenylalanine, levodopa) in the treatment of Parkinson"s disease.	entacapone	55-65	catechol-O-methyltransferase	Rattus norvegicus	30-34
12111468-5	2002	The aim of this study was to examine the effects of the COMT inhibitors entacapone and tolcapone on AC activity in membranes isolated from rat striatum, a brain structure enriched with dopaminergic G-protein-coupled receptors and AC activity.	entacapone	72-82	catechol-O-methyltransferase	Rattus norvegicus	56-60
11806720-3	2002	Of this series, compound 7b (1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone) was found to exhibit the most potent and selective inhibition of peripheral COMT, with an inhibition profile more similar to entacapone 2 than tolcapone 1 (an equipotent peripheral and central inhibitor) but with much improved duration of action (7b, 70% inhibition and 2, 25% inhibition at 9 h after administration).	entacapone	205-215	catechol-O-methyltransferase	Rattus norvegicus	156-160
11994054-0	2002	Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin.	entacapone	53-63	catechol-O-methyltransferase	Homo sapiens	14-42
11994054-1	2002	AIMS: To investigate the influence of a multiple-dose regimen with the catechol-O-methyltransferase inhibitor entacapone on the pharmacokinetics and pharmacodynamics of warfarin.	entacapone	110-120	catechol-O-methyltransferase	Homo sapiens	71-99
11939936-1	2002	OBJECTIVES: To determine the efficacy and safety of the catechol-O-methyltransferase (COMT) inhibitor entacapone, used as an adjunct to levodopa, in Parkinson"s disease (PD) patients.	entacapone	102-112	catechol-O-methyltransferase	Homo sapiens	56-84
11939936-1	2002	OBJECTIVES: To determine the efficacy and safety of the catechol-O-methyltransferase (COMT) inhibitor entacapone, used as an adjunct to levodopa, in Parkinson"s disease (PD) patients.	entacapone	102-112	catechol-O-methyltransferase	Homo sapiens	86-90
11865133-0	2002	COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson"s disease.	entacapone	35-45	catechol-O-methyltransferase	Homo sapiens	0-4
11865133-1	2002	OBJECTIVE: To investigate the relationship between the catechol-O-methyltransferase (COMT) genotype and the therapeutic efficacy of entacapone.	entacapone	132-142	catechol-O-methyltransferase	Homo sapiens	55-83
11865133-1	2002	OBJECTIVE: To investigate the relationship between the catechol-O-methyltransferase (COMT) genotype and the therapeutic efficacy of entacapone.	entacapone	132-142	catechol-O-methyltransferase	Homo sapiens	85-89
11865133-5	2002	Two months of entacapone treatment resulted in a significant increase in "on" time, a reduction in "off" time, and a reduction in the total UPDRS score, but these results were independent of the COMT genotype of the patient.	entacapone	14-24	catechol-O-methyltransferase	Homo sapiens	195-199
11865133-7	2002	CONCLUSION: The COMT genotype seems to be a minor factor in judging the beneficial effects of entacapone administration.	entacapone	94-104	catechol-O-methyltransferase	Homo sapiens	16-20
11732751-1	2001	Entacapone is a new inhibitor of catechol-O-methyltransferase (COMT) that is used as an adjunct to L-dopa therapy in the treatment of Parkinson"s disease.	entacapone	0-10	catechol-O-methyltransferase	Rattus norvegicus	33-61
11978145-16	2002	The COMT inhibitors entacapone and tolcapone dose-dependently inhibit the formation of the major metabolite of levodopa, 3-O-methyldopa, and improve the bioavailability and reduce the clearance of levodopa without significantly affecting its absorption.	entacapone	20-30	catechol-O-methyltransferase	Homo sapiens	4-8
11844927-8	2002	In later disease when patients have already developed motor complications on levodopa, the choice rests between adjuvant therapy with a dopamine agonist, a catechol-O-methyltransferase inhibitor (COMT; e.g. entacapone), and a monoamine oxidase B inhibitor (MAO B; e.g. selegiline).	entacapone	207-217	catechol-O-methyltransferase	Homo sapiens	196-200
11793162-0	2002	Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys.	entacapone	73-83	catechol-O-methyltransferase	Homo sapiens	58-62
11732751-1	2001	Entacapone is a new inhibitor of catechol-O-methyltransferase (COMT) that is used as an adjunct to L-dopa therapy in the treatment of Parkinson"s disease.	entacapone	0-10	catechol-O-methyltransferase	Rattus norvegicus	63-67
11586115-2	2001	Tolcapone and entacapone are two currently available catechol- O -methyltransferase inhibitors that have demonstrated efficacy in the treatment of advanced PD.	entacapone	14-24	catechol-O-methyltransferase	Homo sapiens	53-83
11290882-8	2001	Peripheral COMT inhibition with entacapone does not significantly alter cardiovascular autonomic responses in L-Dopa-treated patients with PD.	entacapone	32-42	catechol-O-methyltransferase	Homo sapiens	11-15
11498717-2	2001	OBJECTIVES: This study assessed the behavioural and pharmacokinetic effects of chronic oral administration of L-dopa plus carbidopa alone, or with co-administration of the peripheral COMT inhibitor entacapone, to normal macaque monkeys.	entacapone	198-208	catechol-O-methyltransferase	Homo sapiens	183-187
11498717-3	2001	Repeated high dose L-dopa administration was shown to induce marked dyskinesias in monkeys with an intact nigrostriatal system, and the threshold for dyskinesia expression was increased by peripheral catechol-O-methyltransferase inhibition with entacapone.	entacapone	245-255	catechol-O-methyltransferase	Homo sapiens	200-228
11510881-2	2001	We have previously shown that inhibition of COMT by entacapone results in a potent D1-like receptor-mediated natriuretic response.	entacapone	52-62	catechol-O-methyltransferase	Rattus norvegicus	44-48
11440283-0	2001	Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson"s disease.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	14-42
11440283-4	2001	Entacapone is a selective inhibitor of COMT whose activity is primarily in the peripheral nervous system, with little effect in the central nervous system.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	39-43
11391126-5	2001	Entacapone decreased the COMT activity from predose level: 100 mg by 25%, 200 mg by 33%, and 400 mg by 32% (p < 0.001 vs. placebo for each dose).	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	25-29
11391126-12	2001	The study showed that repeated dosing of entacapone inhibits the COMT activity in a dose-dependent manner and thereby reduces the loss of L-Dopa to 3-OMD.	entacapone	41-51	catechol-O-methyltransferase	Homo sapiens	65-69
11318939-1	2001	BACKGROUND: In recent years, several nitrocatechol derivatives (tolcapone, entacapone, and nitecapone) have been developed and found to be highly selective and potent inhibitors of catechol-O-methyltransferase (COMT).	entacapone	75-85	catechol-O-methyltransferase	Rattus norvegicus	181-209
11318939-1	2001	BACKGROUND: In recent years, several nitrocatechol derivatives (tolcapone, entacapone, and nitecapone) have been developed and found to be highly selective and potent inhibitors of catechol-O-methyltransferase (COMT).	entacapone	75-85	catechol-O-methyltransferase	Rattus norvegicus	211-215
11160877-8	2001	Among the catechol drugs used in the L-DOPA treatment of Parkinson"s disease, the COMT inhibitors entacapone and tolcapone were not methylated, whereas the DOPA decarboxylase inhibitor benserazide was 15 times more specific substrate than L-DOPA, the target of COMT inhibition.	entacapone	98-108	catechol-O-methyltransferase	Homo sapiens	82-86
11294372-0	2001	Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man.	entacapone	20-30	catechol-O-methyltransferase	Homo sapiens	54-82
11294372-2	2001	OBJECTIVE: This study investigated the pharmacokinetics of the catechol-O-methyltransferase (COMT) inhibitor entacapone by giving simultaneously stable non-radioactive isotope 13C-entacapone intravenously (i.v.)	entacapone	109-119	catechol-O-methyltransferase	Homo sapiens	63-91
11294372-2	2001	OBJECTIVE: This study investigated the pharmacokinetics of the catechol-O-methyltransferase (COMT) inhibitor entacapone by giving simultaneously stable non-radioactive isotope 13C-entacapone intravenously (i.v.)	entacapone	109-119	catechol-O-methyltransferase	Homo sapiens	93-97
11261749-1	2001	Entacapone and tolcapone are novel COMT (catechol-O-methyltransferase) inhibitors indicated for the adjunctive treatment of Parkinson"s disease (PD) in combination with levodopa.	entacapone	0-10	catechol-O-methyltransferase	Rattus norvegicus	35-39
11261749-1	2001	Entacapone and tolcapone are novel COMT (catechol-O-methyltransferase) inhibitors indicated for the adjunctive treatment of Parkinson"s disease (PD) in combination with levodopa.	entacapone	0-10	catechol-O-methyltransferase	Rattus norvegicus	41-69
11261749-9	2001	We conclude that the toxicological profile of the two COMT inhibitors, entacapone and tolcapone, differ from each other, tolcapone--unlike entacapone--showed hepatotoxicity.	entacapone	71-81	catechol-O-methyltransferase	Rattus norvegicus	54-58
11314772-2	2001	To investigate this hypothesis, the acute effects of two doses of the systemically administered COMT inhibitors entacapone (peripheral) and tolcapone (peripheral and central) on the extracellular formation of hydroxyl radicals in vivo following treatment with L-DOPA and the AADC inhibitor carbidopa were examined.	entacapone	112-122	catechol-O-methyltransferase	Rattus norvegicus	96-100
10703007-4	2000	We review data, especially on the remaining COMT inhibitor, entacapone, with regard to pre-clinical and clinical efficacy and safety.	entacapone	60-70	catechol-O-methyltransferase	Homo sapiens	44-48
11244274-1	2001	Entacapone is a potent, reversible and orally active inhibitor of catechol-O-methyltransferase.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	66-94
11038168-1	2000	The COMT inhibitors entacapone and tolcapone are rapidly metabolized in vivo, mainly by glucuronidation.	entacapone	20-30	catechol-O-methyltransferase	Homo sapiens	4-8
11038168-3	2000	Entacapone in particular was seen to be an exceptionally good substrate for UGT1A9 with an even higher reaction velocity value at 500 microM substrate concentration compared with that of the commonly used substrate, propofol (1.3 and 0.78 nmol min(-1) mg(-1), respectively).	entacapone	0-10	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	76-82
11038168-6	2000	However, UGT1A1 was the only UGT capable of catalyzing the formation of two glucuronides of the catecholic entacapone.	entacapone	107-117	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	9-15
11038168-6	2000	However, UGT1A1 was the only UGT capable of catalyzing the formation of two glucuronides of the catecholic entacapone.	entacapone	107-117	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	9-12
11038168-9	2000	The kinetic data illustrates that UGT1A9 exhibited a much greater rate of glucuronidation and a far lower K(m) value for both entacapone and tolcapone than UGT2B15 and UGT2B7 whose contribution is minor by comparison.	entacapone	126-136	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	34-40
11038168-10	2000	Entacapone showed a 3 to 4 times higher V(max) value and a 4 to 6 times lower K(m) value compared with those of tolcapone both in UGT1A9 cell lysates and in human liver microsomes.	entacapone	0-10	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	130-136
11065170-6	2000	The measurement of enzyme activities and kinetic parameters using p-nitrophenol and nitrocatechol (entacapone) as substrates for UGT1A6 and UGT1A9, respectively, showed that the overall kinetic properties of the enzymes produced by the two systems were similar.	entacapone	99-109	UDP glucuronosyltransferase family 1 member A6	Homo sapiens	129-135
11065170-6	2000	The measurement of enzyme activities and kinetic parameters using p-nitrophenol and nitrocatechol (entacapone) as substrates for UGT1A6 and UGT1A9, respectively, showed that the overall kinetic properties of the enzymes produced by the two systems were similar.	entacapone	99-109	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	140-146
10900396-1	2000	Both the catechol-O-methyltransferase (COMT) inhibitor entacapone and the monoamine oxidase B (MAO-B) inhibitor selegiline are L-dopa extenders.	entacapone	55-65	catechol-O-methyltransferase	Homo sapiens	9-37
10900396-1	2000	Both the catechol-O-methyltransferase (COMT) inhibitor entacapone and the monoamine oxidase B (MAO-B) inhibitor selegiline are L-dopa extenders.	entacapone	55-65	catechol-O-methyltransferase	Homo sapiens	39-43
10900396-6	2000	or both entacapone and selegiline with the L-dopa/DDC inhibitor medication.	entacapone	8-18	dopa decarboxylase	Homo sapiens	50-53
10900396-15	2000	Our results suggest that co-administration of entacapone with L-dopa/DDC inhibitor, with or without selegiline, improves clinical disability, is safe, but may also enhance dopamine-related adverse events to some extent in PD patients with end-of-dose type motor fluctuations.	entacapone	46-56	dopa decarboxylase	Homo sapiens	69-72
10981253-1	2000	OBJECTIVE: To introduce entacapone, a new catechol-O-methyltransferase inhibitor, and discuss its pharmacology, pharmacodynamics, pharmacokinetics, clinical efficacy, drug interactions, adverse events, dosage guidelines, and therapeutic and formulary considerations.	entacapone	24-34	catechol-O-methyltransferase	Homo sapiens	42-70
10981253-6	2000	DATA SYNTHESIS: Entacapone is the second medication of a new class of drugs, the catechol-O-methyltransferase inhibitors, indicated for clinical use as an adjunct to levodopa/carbidopa to treat patients with idiopathic Parkinson"s disease who experience the signs and symptoms of end-of-dose wearing-off.	entacapone	16-26	catechol-O-methyltransferase	Homo sapiens	81-109
10882160-2	2000	Entacapone and tolcapone are new potent, selective and reversible nitrocatechol-type COMT inhibitors.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	85-89
10882160-4	2000	In human volunteers, both entacapone and tolcapone dose-dependently inhibit the COMT activity in erythrocytes, improve the bioavailability and decrease the elimination of levodopa, and inhibit the formation of 3-O-methyldopa (3-OMD).	entacapone	26-36	catechol-O-methyltransferase	Homo sapiens	80-84
10766888-0	2000	The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson"s disease.	entacapone	50-60	catechol-O-methyltransferase	Homo sapiens	4-32
10766888-0	2000	The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson"s disease.	entacapone	50-60	catechol-O-methyltransferase	Homo sapiens	34-38
10766888-1	2000	OBJECTIVES: Entacapone is a specific, potent, peripherally acting catechol-O-methyltransferase (COMT) inhibitor.	entacapone	12-22	catechol-O-methyltransferase	Homo sapiens	66-94
10766888-1	2000	OBJECTIVES: Entacapone is a specific, potent, peripherally acting catechol-O-methyltransferase (COMT) inhibitor.	entacapone	12-22	catechol-O-methyltransferase	Homo sapiens	96-100
10858804-2	2000	This consensus statement provides guidelines for the optimal use of the only currently available COMT inhibitor, entacapone (Comtess, Orion Pharma (UK) Ltd, Newbury, Berkshire).	entacapone	113-123	catechol-O-methyltransferase	Homo sapiens	97-101
11147507-4	2000	Two COMT inhibitors, tolcapone and entacapone, have recently been introduced as adjuncts to levodopa to further inhibit peripheral levodopa metabolism and thereby enhance brain levodopa availability.	entacapone	35-45	catechol-O-methyltransferase	Homo sapiens	4-8
10733264-15	2000	Entacapone, a purely peripheral COMT inhibitor with a lower potency than tolcapone, has also proved to be effective and has not been associated with liver damage, obviating the need for testing.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	32-36
11147510-1	2000	This paper reviews the issue of hepatotoxicity with the use of the catechol-O-methly transferase (COMT) inhibitors tolcapone and entacapone.	entacapone	129-139	catechol-O-methyltransferase	Homo sapiens	98-102
11147511-1	2000	Two inhibitors of catechol-O-methyl transferase (COMT), tolcapone and entacapone, have recently been introduced as adjuncts to levodopa in the treatment of Parkinson"s disease patients.	entacapone	70-80	catechol-O-methyltransferase	Homo sapiens	18-47
11147511-1	2000	Two inhibitors of catechol-O-methyl transferase (COMT), tolcapone and entacapone, have recently been introduced as adjuncts to levodopa in the treatment of Parkinson"s disease patients.	entacapone	70-80	catechol-O-methyltransferase	Homo sapiens	49-53
11147512-2	2000	Two COMT inhibitors, tolcapone and entacapone, have recently been made available as adjunctive agents to levodopa.	entacapone	35-45	catechol-O-methyltransferase	Homo sapiens	4-8
11503812-2	1999	(1) Entacapone, a catechol-O-methyltransferase inhibitor, is indicated, in combination with levodopa + a dopadecarboxylase inhibitor, for the treatment of parkinsonian patients who have motor fluctuations on levodopa therapy.	entacapone	4-14	catechol-O-methyltransferase	Homo sapiens	18-46
11147508-2	2000	This paper examines the pharmacology of COMT inhibitors such as tolcapone and entacapone, and considers the effects of these drugs on the pharmacolinetics of levodopa.	entacapone	78-88	catechol-O-methyltransferase	Homo sapiens	40-44
11147509-1	2000	Recent prospective, double-blind, placebo-controlled trials have examined the long-term effects of the catechol-O-methyl transferase (COMT) inhibitors entacapone and tolcapone as adjuncts to levodopa in PD patients with wearing-off motor fluctuations.	entacapone	151-161	catechol-O-methyltransferase	Homo sapiens	103-132
11147509-1	2000	Recent prospective, double-blind, placebo-controlled trials have examined the long-term effects of the catechol-O-methyl transferase (COMT) inhibitors entacapone and tolcapone as adjuncts to levodopa in PD patients with wearing-off motor fluctuations.	entacapone	151-161	catechol-O-methyltransferase	Homo sapiens	134-138
10555945-4	1999	Entacapone and tolcapone are two potent, selective, and reversible COMT inhibitors that effectively augment levodopa"s pharmacokinetics by increasing area under the plasma concentration versus time curve and plasma elimination half-life without significantly affecting peak levodopa concentrations.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	67-71
10570622-2	1999	Entacapone (Comtan) is a potent, peripherally acting, reversible and selective inhibitor of catechol-O-methyltransferase (COMT).	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	92-120
12973467-2	1999	Entacapone is a potent, selective peripheral catechol O-methyltransferase inhibitor which effectively inhibits the O-methylation of levodopa, thus increasing its central bioavailability and potentiating its behavioral effects.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	45-73
10451758-1	1999	The COMT inhibitors, tolcapone and entacapone, are a new class of Parkinson"s medications.	entacapone	35-45	catechol-O-methyltransferase	Homo sapiens	4-8
10492060-1	1999	OBJECTIVE: Entacapone is a peripherally acting catechol O-methyltransferase (COMT) inhibitor used as an adjunct to each daily levodopa/dopa decarboxylase (DDC) inhibitor dose in the treatment of Parkinson"s disease.	entacapone	11-21	catechol-O-methyltransferase	Homo sapiens	47-75
10492060-1	1999	OBJECTIVE: Entacapone is a peripherally acting catechol O-methyltransferase (COMT) inhibitor used as an adjunct to each daily levodopa/dopa decarboxylase (DDC) inhibitor dose in the treatment of Parkinson"s disease.	entacapone	11-21	catechol-O-methyltransferase	Homo sapiens	77-81
10492060-1	1999	OBJECTIVE: Entacapone is a peripherally acting catechol O-methyltransferase (COMT) inhibitor used as an adjunct to each daily levodopa/dopa decarboxylase (DDC) inhibitor dose in the treatment of Parkinson"s disease.	entacapone	11-21	dopa decarboxylase	Homo sapiens	135-153
10492060-13	1999	Entacapone reduced erythrocyte COMT activity after the first dose, and this effect was quite stable during frequent dosing.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	31-35
10570622-2	1999	Entacapone (Comtan) is a potent, peripherally acting, reversible and selective inhibitor of catechol-O-methyltransferase (COMT).	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	122-126
10570622-2	1999	Entacapone (Comtan) is a potent, peripherally acting, reversible and selective inhibitor of catechol-O-methyltransferase (COMT).	entacapone	12-18	catechol-O-methyltransferase	Homo sapiens	92-120
10570622-2	1999	Entacapone (Comtan) is a potent, peripherally acting, reversible and selective inhibitor of catechol-O-methyltransferase (COMT).	entacapone	12-18	catechol-O-methyltransferase	Homo sapiens	122-126
10439935-2	1999	UNLABELLED: Entacapone is a potent and specific peripheral catechol-O-methyltransferase (COMT) inhibitor.	entacapone	12-22	catechol-O-methyltransferase	Homo sapiens	59-87
10439935-2	1999	UNLABELLED: Entacapone is a potent and specific peripheral catechol-O-methyltransferase (COMT) inhibitor.	entacapone	12-22	catechol-O-methyltransferase	Homo sapiens	89-93
10439935-5	1999	In 2 well conducted trials of 6 months" duration and smaller short term studies, treatment with entacapone (200 mg with each dose of levodopa/AADC inhibitor) was associated with significant increases in daily "on" time and decreases in "off" time.	entacapone	96-106	dopa decarboxylase	Homo sapiens	142-146
10439935-7	1999	Entacapone also provided benefits when given with controlled release levodopa/ AADC inhibitor or with standard levodopa/AADC inhibitor and selegiline in small trials.	entacapone	0-10	dopa decarboxylase	Homo sapiens	79-83
10439935-7	1999	Entacapone also provided benefits when given with controlled release levodopa/ AADC inhibitor or with standard levodopa/AADC inhibitor and selegiline in small trials.	entacapone	0-10	dopa decarboxylase	Homo sapiens	120-124
10439935-11	1999	CONCLUSIONS: The efficacy and tolerability of entacapone administered with levodopa/AADC inhibitor have not yet been compared with those of other strategies for the treatment of Parkinson"s disease.	entacapone	46-56	dopa decarboxylase	Homo sapiens	84-88
10363328-1	1999	Entacapone (Comtan) is a potent, selective inhibitor of peripheral catechol-O-methyltransferase (COMT) with therapeutic potential as an adjuvant to levodopa therapy in patients with Parkinson"s disease.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	67-95
10363328-1	1999	Entacapone (Comtan) is a potent, selective inhibitor of peripheral catechol-O-methyltransferase (COMT) with therapeutic potential as an adjuvant to levodopa therapy in patients with Parkinson"s disease.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	97-101
10363328-1	1999	Entacapone (Comtan) is a potent, selective inhibitor of peripheral catechol-O-methyltransferase (COMT) with therapeutic potential as an adjuvant to levodopa therapy in patients with Parkinson"s disease.	entacapone	12-18	catechol-O-methyltransferase	Homo sapiens	67-95
10363328-1	1999	Entacapone (Comtan) is a potent, selective inhibitor of peripheral catechol-O-methyltransferase (COMT) with therapeutic potential as an adjuvant to levodopa therapy in patients with Parkinson"s disease.	entacapone	12-18	catechol-O-methyltransferase	Homo sapiens	97-101
9808337-1	1998	A new approach in the treatment of Parkinson"s disease is the inhibition of catechol-O-methyltransferase (COMT) with new generation COMT inhibitors, entacapone and tolcapone.	entacapone	149-159	catechol-O-methyltransferase	Homo sapiens	76-104
15992091-0	1999	Entacapone, a catechol-O-methyltransferase inhibitor for treating Parkinson"s disease: review and current status.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	14-42
15992091-3	1999	Entacapone (Comtan) is a selective, reversible catechol-O-methyltransferase inhibitor that dose-dependently increases the peripheral bioavailability of levodopa and prolongs its duration of action.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	47-75
15992091-3	1999	Entacapone (Comtan) is a selective, reversible catechol-O-methyltransferase inhibitor that dose-dependently increases the peripheral bioavailability of levodopa and prolongs its duration of action.	entacapone	12-18	catechol-O-methyltransferase	Homo sapiens	47-75
10220913-2	1999	Entacapone is a novel drug which, as a potent inhibitor of catechol-O-methyltransferase (COMT), is used as an adjunct in the standard therapy of Parkinson"s disease.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	59-87
10220913-2	1999	Entacapone is a novel drug which, as a potent inhibitor of catechol-O-methyltransferase (COMT), is used as an adjunct in the standard therapy of Parkinson"s disease.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	89-93
10229966-0	1999	[Entacapone++ : a new catechol-O-methyltransferase inhibitor which improves the response to levodopa in patients with Parkinson disease and fluctuating motor function].	entacapone	1-11	catechol-O-methyltransferase	Homo sapiens	22-50
10027643-2	1999	Entacapone is a novel, potent inhibitor of catechol-O-methyltransferase (COMT) intended for use as an adjunct in the treatment of Parkinson"s disease.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	43-71
10027643-2	1999	Entacapone is a novel, potent inhibitor of catechol-O-methyltransferase (COMT) intended for use as an adjunct in the treatment of Parkinson"s disease.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	73-77
10410761-0	1999	COMT inhibition with entacapone in the treatment of Parkinson"s disease.	entacapone	21-31	catechol-O-methyltransferase	Homo sapiens	0-4
9808337-1	1998	A new approach in the treatment of Parkinson"s disease is the inhibition of catechol-O-methyltransferase (COMT) with new generation COMT inhibitors, entacapone and tolcapone.	entacapone	149-159	catechol-O-methyltransferase	Homo sapiens	106-110
9808337-9	1998	Based on the duration of COMT inhibition entacapone is administered with each levodopa/DDC inhibitor dose whereas tolcapone is given three times daily.	entacapone	41-51	catechol-O-methyltransferase	Homo sapiens	25-29
9818851-3	1998	BACKGROUND: Entacapone is a catechol-O-methyltransferase (COMT) inhibitor that has been shown to increase the area under the concentration-time curve of plasma levodopa by decreasing its systemic elimination, thereby promoting and improving therapeutic response to it.	entacapone	12-22	catechol-O-methyltransferase	Homo sapiens	28-56
9818851-3	1998	BACKGROUND: Entacapone is a catechol-O-methyltransferase (COMT) inhibitor that has been shown to increase the area under the concentration-time curve of plasma levodopa by decreasing its systemic elimination, thereby promoting and improving therapeutic response to it.	entacapone	12-22	catechol-O-methyltransferase	Homo sapiens	58-62
9633684-4	1998	The new nitrocatechol-type COMT inhibitors entacapone, nitecapone, and tolcapone inhibit COMT in the periphery; tolcapone also inhibits COMT activity centrally.	entacapone	43-53	catechol-O-methyltransferase	Homo sapiens	27-31
9633684-4	1998	The new nitrocatechol-type COMT inhibitors entacapone, nitecapone, and tolcapone inhibit COMT in the periphery; tolcapone also inhibits COMT activity centrally.	entacapone	43-53	catechol-O-methyltransferase	Homo sapiens	89-93
9633684-4	1998	The new nitrocatechol-type COMT inhibitors entacapone, nitecapone, and tolcapone inhibit COMT in the periphery; tolcapone also inhibits COMT activity centrally.	entacapone	43-53	catechol-O-methyltransferase	Homo sapiens	89-93
9358559-8	1997	The kinetic parameters for COMT inhibitors were in the following order: K(m) nitecapone &gt; &gt; entacapone &gt; tolcapone; Vmax nitecapone &gt; entacapone &gt; tolcapone; Vmax/K(m) tolcapone &gt; nitecapone &gt; entacapone.	entacapone	98-108	catechol-O-methyltransferase	Rattus norvegicus	27-31
9681662-0	1998	Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone.	entacapone	77-87	catechol-O-methyltransferase	Homo sapiens	0-28
9681662-1	1998	OBJECTIVE: The aim of this investigation was to study the variation of catechol-O-methyltransferase (COMT) activity in the human liver, duodenal mucosa and renal cortex, and to investigate the inhibition of COMT by entacapone and tolcapone.	entacapone	215-225	catechol-O-methyltransferase	Homo sapiens	101-105
9681662-1	1998	OBJECTIVE: The aim of this investigation was to study the variation of catechol-O-methyltransferase (COMT) activity in the human liver, duodenal mucosa and renal cortex, and to investigate the inhibition of COMT by entacapone and tolcapone.	entacapone	215-225	catechol-O-methyltransferase	Homo sapiens	207-211
9681662-7	1998	CONCLUSION: Entacapone and tolcapone were powerful inhibitors of COMT and their IC50 estimates were 151 and 773 nM (P = 0.008), respectively, in the liver; consistent results were obtained with the other tissues.	entacapone	12-22	catechol-O-methyltransferase	Homo sapiens	65-69
9591516-4	1998	This review focuses on the role of the new catechol O-methyltransferase (COMT) inhibitors tolcapone and entacapone as adjuncts to levodopa therapy.	entacapone	104-114	catechol-O-methyltransferase	Homo sapiens	43-71
9591516-4	1998	This review focuses on the role of the new catechol O-methyltransferase (COMT) inhibitors tolcapone and entacapone as adjuncts to levodopa therapy.	entacapone	104-114	catechol-O-methyltransferase	Homo sapiens	73-77
9591519-3	1998	Two basic classes of COMT inhibitors are being studied in patients with PD: those that act exclusively extracerebrally or peripherally (e.g., entacapone) and those that cross the blood-brain barrier (e.g., tolcapone).	entacapone	142-152	catechol-O-methyltransferase	Homo sapiens	21-25
9610919-0	1998	Conditioned place preference induced by a combination of L-dopa and a COMT inhibitor, entacapone, in rats.	entacapone	86-96	catechol-O-methyltransferase	Rattus norvegicus	70-74
9610919-1	1998	The interaction of dopamine (DA) precursor L-dopa and catechol-O-methyltransferase (COMT) inhibitor, entacapone, was examined in rats using conditioned place preference (CPP) paradigm to assess reinforcement, and by measuring DA metabolism in the striatum and the limbic forebrain.	entacapone	101-111	catechol-O-methyltransferase	Rattus norvegicus	54-82
9610919-1	1998	The interaction of dopamine (DA) precursor L-dopa and catechol-O-methyltransferase (COMT) inhibitor, entacapone, was examined in rats using conditioned place preference (CPP) paradigm to assess reinforcement, and by measuring DA metabolism in the striatum and the limbic forebrain.	entacapone	101-111	catechol-O-methyltransferase	Rattus norvegicus	84-88
9610919-5	1998	Entacapone alone had no effect on limbic or striatal DA concentrations, while it reduced the concentrations of the COMT products 3-methoxytyramine (3-MT), a metabolite reflecting DA release, and homovanillic acid (HVA) in both brain areas.	entacapone	0-10	catechol-O-methyltransferase	Rattus norvegicus	115-119
9597116-6	1998	Pretreatment with the selective dopamine DA1-receptor antagonist SCH23390 reduced the entacapone-induced natriuretic response by 69%.	entacapone	86-96	RT1 class II, locus Da	Rattus norvegicus	41-44
9597116-10	1998	In conclusion, COMT inhibition using entacapone results in a mainly DA1 receptor mediated natriuresis involving inhibition of tubular transport processes, supporting a role for dopamine metabolism in sodium homeostasis.	entacapone	37-47	catechol-O-methyltransferase	Rattus norvegicus	15-19
9597116-10	1998	In conclusion, COMT inhibition using entacapone results in a mainly DA1 receptor mediated natriuresis involving inhibition of tubular transport processes, supporting a role for dopamine metabolism in sodium homeostasis.	entacapone	37-47	RT1 class II, locus Da	Rattus norvegicus	68-71
9537825-0	1997	Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson"s disease, does not impair mitochondrial energy production.	entacapone	0-10	catechol-O-methyltransferase	Mus musculus	20-48
9537825-1	1997	Entacapone, a novel mainly peripherally acting catechol-O-methyltransferase inhibitor used in the treatment of Parkinson"s disease, was evaluated for its possible uncoupling activity in cell culture, in rat liver mitochondria, and in isolated guinea-pig heart.	entacapone	0-10	catechol-O-methyltransferase	Rattus norvegicus	47-75
9537825-8	1997	These results show that peripherally acting entacapone, unlike the brain-penetrating tolcapone, is a safe catechol-O-methyltransferase inhibitor for the treatment of Parkinson"s disease, since it does not interfere with mitochondrial energy metabolism at pharmacologically effective concentrations.	entacapone	44-54	catechol-O-methyltransferase	Mus musculus	106-134
9372556-1	1997	The aim was to investigate the effects of inhibition of monoamine oxidase type B (MAO-B) with selegiline alone and the combined inhibition of peripheral catechol-O-methyltransferase (COMT) with entacapone and MAO-B with selegiline on striatal 6-[18F]fluorodopa (FDOPA) accumulation, and whether the effect of entacapone + selegiline on FDOPA uptake differed depending on the severity of the presynaptic dopaminergic dysfunction.	entacapone	194-204	catechol-O-methyltransferase	Homo sapiens	183-187
9392574-3	1997	Entacapone, a peripherally acting, reversible inhibitor of catechol-O-methyltransferase, slows the elimination of levodopa in humans by reducing the formation of 3-O-methyldopa.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	59-87
9399218-3	1997	Pretreatment with the peripheral COMT inhibitor entacapone (12.5 mg/kg p.o.)	entacapone	48-58	catechol O-methyltransferase	Callithrix jacchus	33-37
9337447-13	1997	The COMT inhibitors, tolcapone and entacapone, improve the pharmacokinetics of levodopa by preventing its peripheral catabolism and increasing the concentration of brain dopamine; thus, these agents may reduce the incidence of "wearing-off" effects associated with the short half-life of levodopa and the progression of Parkinson"s disease.	entacapone	35-45	catechol-O-methyltransferase	Homo sapiens	4-8
9337447-17	1997	The COMT inhibitors, entacapone and tolcapone, have also demonstrated efficacy in improving on-time in patients with stable disease.	entacapone	21-31	catechol-O-methyltransferase	Homo sapiens	4-8
9358559-8	1997	The kinetic parameters for COMT inhibitors were in the following order: K(m) nitecapone &gt; &gt; entacapone &gt; tolcapone; Vmax nitecapone &gt; entacapone &gt; tolcapone; Vmax/K(m) tolcapone &gt; nitecapone &gt; entacapone.	entacapone	146-156	catechol-O-methyltransferase	Rattus norvegicus	27-31
9358559-8	1997	The kinetic parameters for COMT inhibitors were in the following order: K(m) nitecapone &gt; &gt; entacapone &gt; tolcapone; Vmax nitecapone &gt; entacapone &gt; tolcapone; Vmax/K(m) tolcapone &gt; nitecapone &gt; entacapone.	entacapone	146-156	catechol-O-methyltransferase	Rattus norvegicus	27-31
8784230-3	1996	Pretreatment with entacapone (OR-611), a peripheral catechol O-methyl-transferase (COMT) inhibitor, greatly reduces the plasma 3OMFD fraction and provides an ideal situation to evaluate the contribution of the plasma 3OMFD fraction in several kinetic models of FDOPA uptake.	entacapone	18-28	catechol-O-methyltransferase	Homo sapiens	83-87
9232524-0	1997	Iron(III)-chelating properties of the novel catechol O-methyltransferase inhibitor entacapone in aqueous solution.	entacapone	83-93	catechol-O-methyltransferase	Homo sapiens	44-72
9232524-1	1997	The iron(III) complex formation of entacapone, a novel catechol O-methyltransferase (COMT) inhibitor, has been studied at 25 degrees C in aqueous 0.1 mol/L NaCl solution by using the electromotive force titration method.	entacapone	35-45	catechol-O-methyltransferase	Homo sapiens	55-83
9232524-1	1997	The iron(III) complex formation of entacapone, a novel catechol O-methyltransferase (COMT) inhibitor, has been studied at 25 degrees C in aqueous 0.1 mol/L NaCl solution by using the electromotive force titration method.	entacapone	35-45	catechol-O-methyltransferase	Homo sapiens	85-89
9251066-13	1997	Entacapone decreased erythrocyte COMT activity by > 35% (p < 0.001), and platelet MAO-B activity was almost completely inhibited by selegiline (p < 0.001).	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	33-37
9105581-1	1997	The effects of new selective catechol-O-methyltransferase (COMT) inhibitors entacapone (mainly peripheral effect) and tolcapone (acting also in the brain) on normal and impaired cognitive functions were studied in aversively motivated inhibitory avoidance using a single-trial passive avoidance paradigm in young adult rats.	entacapone	76-86	catechol-O-methyltransferase	Rattus norvegicus	59-63
8784230-3	1996	Pretreatment with entacapone (OR-611), a peripheral catechol O-methyl-transferase (COMT) inhibitor, greatly reduces the plasma 3OMFD fraction and provides an ideal situation to evaluate the contribution of the plasma 3OMFD fraction in several kinetic models of FDOPA uptake.	entacapone	30-36	catechol-O-methyltransferase	Homo sapiens	83-87
8726541-8	1996	Peripheral COMT inhibition with entacapone increased significantly the bioavailability of levodopa and prolonged its antiparkinsonian effect after a single dose and after repeated dosing for 4 weeks.	entacapone	32-42	catechol-O-methyltransferase	Homo sapiens	11-15
24283686-1	1995	We investigated clinical response and pharmacokinetics of levodopa when entacapone, a catechol O-methyltransferase (COMT) inhibitor, was administered concomitantly with either a standard (Std) or a controlled-release (CR) levodopa/carbidopa preparation to 12 patients with Parkinson"s disease.	entacapone	72-82	catechol-O-methyltransferase	Homo sapiens	116-120
8612391-2	1996	BACKGROUND: Entacapone, a COMT inhibitor, is studied as an adjunct to levodopa treatment in patients with Parkinson"s disease.	entacapone	12-22	catechol-O-methyltransferase	Homo sapiens	26-30
8612391-5	1996	It was therefore considered to be important to investigate the tolerability of combined COMT and MAO-A inhibition with entacapone and moclobemide.	entacapone	119-129	catechol-O-methyltransferase	Homo sapiens	88-92
8738181-9	1996	For both normal volunteers and patients having Parkinson"s disease, a single 400 mg dose of entacapone, a peripherally acting COMT inhibitor, decreased the erythrocyte COMT activity.	entacapone	92-102	catechol-O-methyltransferase	Homo sapiens	126-130
8738181-9	1996	For both normal volunteers and patients having Parkinson"s disease, a single 400 mg dose of entacapone, a peripherally acting COMT inhibitor, decreased the erythrocyte COMT activity.	entacapone	92-102	catechol-O-methyltransferase	Homo sapiens	168-172
9010698-1	1996	OBJECTIVE: We have evaluated the effects of simultaneous inhibition of catechol-O-methyltransferase (COMT) by entacapone and of neuronal monoamine reuptake by imipramine on haemodynamics and catecholamine metabolism, and the safety and tolerability of the drug combination in healthy women.	entacapone	110-120	catechol-O-methyltransferase	Homo sapiens	71-99
9010698-1	1996	OBJECTIVE: We have evaluated the effects of simultaneous inhibition of catechol-O-methyltransferase (COMT) by entacapone and of neuronal monoamine reuptake by imipramine on haemodynamics and catecholamine metabolism, and the safety and tolerability of the drug combination in healthy women.	entacapone	110-120	catechol-O-methyltransferase	Homo sapiens	101-105
8836934-0	1996	COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers.	entacapone	19-29	catechol-O-methyltransferase	Homo sapiens	0-4
8836934-1	1996	We studied the effects of entacapone, a novel inhibitor of the enzyme catechol-O-methyltransferase (COMT), on spontaneous and levodopa (LD) modulated secretion of growth hormone (GH) and prolactin (PRL) in 12 healthy male volunteers.	entacapone	26-36	catechol-O-methyltransferase	Homo sapiens	100-104
8836934-5	1996	Entacapone had no effect on resting levels of GH, but PRL concentrations in plasma were slightly lower after entacapone than after placebo.	entacapone	109-119	prolactin	Homo sapiens	54-57
8836934-8	1996	Compared with the administration of LD/carbidopa together with placebo, concomitant administration of entacapone increased the AUC of LD by 29% and reduced the AUC of 3-O-methyldopa (a metabolite of LD produced by COMT) by 69%.	entacapone	102-112	catechol-O-methyltransferase	Homo sapiens	214-218
8558148-1	1996	OBJECTIVES: To establish, in a double blind manner, the antiparkinsonian effects of repeated dosing with entacapone, a peripheral COMT inhibitor.	entacapone	105-115	catechol-O-methyltransferase	Homo sapiens	130-134
24283686-1	1995	We investigated clinical response and pharmacokinetics of levodopa when entacapone, a catechol O-methyltransferase (COMT) inhibitor, was administered concomitantly with either a standard (Std) or a controlled-release (CR) levodopa/carbidopa preparation to 12 patients with Parkinson"s disease.	entacapone	72-82	catechol-O-methyltransferase	Homo sapiens	86-114
24283686-21	1995	The study shows that entacapone is an effective COMT inhibitor when combined with either Std levodopa or CR levodopa.	entacapone	21-31	catechol-O-methyltransferase	Homo sapiens	48-52
7874370-0	1994	COMT inhibition by high-dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise.	entacapone	29-39	catechol-O-methyltransferase	Homo sapiens	0-4
7648772-1	1995	BACKGROUND: Entacapone is a potent, selective catechol-O-methyltransferase (COMT) inhibitor.	entacapone	12-22	catechol-O-methyltransferase	Homo sapiens	46-74
7648772-1	1995	BACKGROUND: Entacapone is a potent, selective catechol-O-methyltransferase (COMT) inhibitor.	entacapone	12-22	catechol-O-methyltransferase	Homo sapiens	76-80
7648772-2	1995	Entacapone could potentiate the hemodynamic effects of exogenously administered catecholamines, which are substrates of the COMT enzyme.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	124-128
8665534-0	1995	Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers.	entacapone	10-20	catechol-O-methyltransferase	Homo sapiens	24-28
8665534-1	1995	We studied the effect of entacapone, a catechol-O-methyltransferase (COMT) inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of a controlled-release (CR) levodopa-carbidopa preparation (Sinemet CR) in an open, randomized trial in 12 healthy male volunteers.	entacapone	25-35	catechol-O-methyltransferase	Homo sapiens	69-73
8665534-5	1995	Entacapone decreased dose-dependently the activity of S-COMT in RBCs with a maximal inhibition of 66% after the highest dose (800 mg).	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	56-60
8665534-12	1995	Entacapone is an effective COMT inhibitor.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	27-31
9620057-0	1995	Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson"s disease.	entacapone	64-74	catechol-O-methyltransferase	Homo sapiens	43-47
7874370-11	1994	COMT inhibition by entacapone seems not to affect hemodynamics or plasma concentrations of unconjugated adrenaline and noradrenaline in healthy volunteers either at rest or during exercise.	entacapone	19-29	catechol-O-methyltransferase	Homo sapiens	0-4
8001593-0	1994	Metabolite profiles of two [14C]-labelled catechol O-methyltransferase inhibitors, nitecapone and entacapone, in rat and mouse urine and rat bile.	entacapone	98-108	catechol-O-methyltransferase	Rattus norvegicus	42-70
7835624-4	1994	Entacapone, nitecapone and tolcapone are nitrocatechol-type potent COMT inhibitors in vitro (Ki in nanomolar range).	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	67-71
7835624-12	1994	In man, entacapone, nitecapone and tolcapone all inhibit dose dependently the COMT activity in erythrocytes.	entacapone	8-18	catechol-O-methyltransferase	Homo sapiens	78-82
8035933-1	1994	We used PET and [18F]-6-L-fluorodopa ([18F]dopa) to measure the effect of a peripheral COMT inhibitor, entacapone, on the extracerebral metabolism and subsequent striatal uptake of [18F]dopa.	entacapone	103-113	catechol-O-methyltransferase	Homo sapiens	87-91
8082707-2	1994	We studied the effects of entacapone, a peripheral catechol-O-methyl transferase inhibitor, on striatal [18F]fluoro-DOPA uptake in rats.	entacapone	26-36	catechol-O-methyltransferase	Rattus norvegicus	51-80
7518301-7	1994	In the presence of L-dopa/carbidopa, a peripherally active inhibitor of catechol O-methyltransferase (COMT) entacapone had a short-lasting increasing effect on L-dopa efflux.	entacapone	108-118	catechol-O-methyltransferase	Rattus norvegicus	72-100
7518301-7	1994	In the presence of L-dopa/carbidopa, a peripherally active inhibitor of catechol O-methyltransferase (COMT) entacapone had a short-lasting increasing effect on L-dopa efflux.	entacapone	108-118	catechol-O-methyltransferase	Rattus norvegicus	102-106
7518301-17	1994	Our results demonstrate that entacapone is a peripheral COMT inhibitor and support the view that CGP 18014 is mainly a centrally acting inhibitor of O-methylation.	entacapone	29-39	catechol-O-methyltransferase	Rattus norvegicus	56-60
8190296-9	1994	We conclude that inhibition of COMT by entacapone increases the plasma half-life of levodopa and augments the antiparkinsonian effects of single and repeated doses of levodopa.	entacapone	39-49	catechol-O-methyltransferase	Homo sapiens	31-35
27520516-2	1994	Entacapone, nitecapone and to1capone are nitrocatechol- type agents that are potent COMT inhibitors in vitro and are active in vivo after oral administration.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	84-88
27520516-5	1994	In human volunteers, entacapone, nitecapone and tolcapone inhibit dose-dependently COMT activity of erythrocytes.	entacapone	21-31	catechol-O-methyltransferase	Homo sapiens	83-87
27520516-6	1994	COMT inhibitors also decrease the levels of COMT-dependent metabolites of adrenaline (epinephrine) and noradrenaline (norepinephrine) in plasma.Entacapone, to1capone and CGP 28014 improve the bioavailability of levodopa and inhibit the formation of 3-0-methyldopa in human volunteers.	entacapone	144-154	catechol-O-methyltransferase	Homo sapiens	0-4
27520516-6	1994	COMT inhibitors also decrease the levels of COMT-dependent metabolites of adrenaline (epinephrine) and noradrenaline (norepinephrine) in plasma.Entacapone, to1capone and CGP 28014 improve the bioavailability of levodopa and inhibit the formation of 3-0-methyldopa in human volunteers.	entacapone	144-154	catechol-O-methyltransferase	Homo sapiens	44-48
8020535-0	1993	Identification of major urinary metabolites of the catechol-O-methyltransferase inhibitor entacapone in the dog.	entacapone	90-100	catechol-O-methyltransferase	Canis lupus familiaris	51-79
8126502-0	1994	Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson"s disease.	entacapone	10-20	catechol-O-methyltransferase	Homo sapiens	44-72
8039535-0	1994	Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone.	entacapone	129-139	catechol-O-methyltransferase	Homo sapiens	22-50
8039535-1	1994	The inhibition of soluble catechol-O-methyl-transferase (S-COMT) in red blood cells (RBCs) by entacapone, and the pharmacokinetics of entacapone after single oral (5-800 mg) and i.v.	entacapone	94-104	catechol-O-methyltransferase	Homo sapiens	59-63
8039535-3	1994	Oral entacapone dose-dependently decreased the activity of S-COMT in RBCs with a maximum inhibition of 82% after the highest dose (800 mg).	entacapone	5-15	catechol-O-methyltransferase	Homo sapiens	61-65
8039535-4	1994	The inhibition of S-COMT in RBCs was reversible and the activity recovered within 4-8 h. Entacapone showed linear pharmacokinetics over the dose range studied: Cmax and AUC were correlated with the dose of the drug.	entacapone	89-99	catechol-O-methyltransferase	Homo sapiens	20-24
8039535-10	1994	The results show that entacapone is an orally effective and reversible COMT inhibitor in man and has simple, linear pharmacokinetics.	entacapone	22-32	catechol-O-methyltransferase	Homo sapiens	71-75
8290096-0	1994	Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients.	entacapone	10-20	catechol-O-methyltransferase	Homo sapiens	24-28
12959293-0	1993	The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise.	entacapone	34-44	catechol-O-methyltransferase	Homo sapiens	19-23
12959293-4	1993	The purpose of the present study was to establish whether the novel COMT inhibitor, entacapone, changes haemodynamic responses and catecholamine metabolism during exercise.	entacapone	84-94	catechol-O-methyltransferase	Homo sapiens	68-72
8020535-1	1993	Metabolites of entacapone, (E)-2-cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl) propenamide, a potent inhibitor of catechol-O-methyltransferase, were isolated from dog urine.	entacapone	15-25	catechol-O-methyltransferase	Canis lupus familiaris	118-146
8477410-0	1993	The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.	entacapone	58-68	catechol-O-methyltransferase	Homo sapiens	14-43
8341294-0	1993	Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.	entacapone	41-47	catechol-O-methyltransferase	Homo sapiens	26-30
8341294-3	1993	We studied the effect of OR-611, a new COMT inhibitor, on plasma and brain 6-[18F]-fluoro-L-dopa (6FD) metabolism in cynomolgus monkeys with positron emission tomography (PET).	entacapone	25-31	catechol O-methyltransferase	Macaca fascicularis	39-43
8477410-1	1993	We studied the effect of inhibiting the enzyme catechol-O-methyltransferase (COMT) by a novel COMT inhibitor, entacapone, on the pharmacokinetics and metabolism of levodopa in 12 healthy male volunteers.	entacapone	110-120	catechol-O-methyltransferase	Homo sapiens	47-75
8477410-1	1993	We studied the effect of inhibiting the enzyme catechol-O-methyltransferase (COMT) by a novel COMT inhibitor, entacapone, on the pharmacokinetics and metabolism of levodopa in 12 healthy male volunteers.	entacapone	110-120	catechol-O-methyltransferase	Homo sapiens	77-81
8477410-1	1993	We studied the effect of inhibiting the enzyme catechol-O-methyltransferase (COMT) by a novel COMT inhibitor, entacapone, on the pharmacokinetics and metabolism of levodopa in 12 healthy male volunteers.	entacapone	110-120	catechol-O-methyltransferase	Homo sapiens	94-98
8477410-11	1993	The in vivo biochemical effects of entacapone indicate that it is an orally active COMT inhibitor and that it may improve the therapeutic efficacy of levodopa in Parkinson"s disease.	entacapone	35-45	catechol-O-methyltransferase	Homo sapiens	83-87
1628144-12	1992	OR-611 was primarily a peripherally acting COMT inhibitor, decreasing 3-OMD levels in the striatum (to 31-52%) and in the hypothalamus (to 16-27%) both in the control and pargyline-treated animals at 1 and 3 h. It did not have any effect on brain HVA and 3-MT.	entacapone	0-6	catechol-O-methyltransferase	Rattus norvegicus	43-47
8095232-0	1993	Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans.	entacapone	82-92	catechol-O-methyltransferase	Rattus norvegicus	43-71
8095232-1	1993	Metabolites of entacapone [(E)-2-cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide++ +], a potent inhibitor of catechol-O-methyltransferase, were isolated from human and rat urine.	entacapone	15-25	catechol-O-methyltransferase	Homo sapiens	122-150
8112370-0	1993	Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson"s disease.	entacapone	10-20	catechol-O-methyltransferase	Homo sapiens	24-28
8112370-1	1993	In an open, randomised, cross-over study we investigated the effect of a single 200 mg oral dose of entacapone, a novel catechol-O-methyltransferase (COMT) inhibitor, on the pharmacokinetics and metabolism of levodopa/carbidopa, and on the cardiovascular responses (blood pressure and pulse rate variation to standard stimuli) in eight parkinsonian patients.	entacapone	100-110	catechol-O-methyltransferase	Homo sapiens	120-148
8112370-1	1993	In an open, randomised, cross-over study we investigated the effect of a single 200 mg oral dose of entacapone, a novel catechol-O-methyltransferase (COMT) inhibitor, on the pharmacokinetics and metabolism of levodopa/carbidopa, and on the cardiovascular responses (blood pressure and pulse rate variation to standard stimuli) in eight parkinsonian patients.	entacapone	100-110	catechol-O-methyltransferase	Homo sapiens	150-154
1407012-0	1992	Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone.	entacapone	107-117	catechol-O-methyltransferase	Rattus norvegicus	68-96
1407012-1	1992	Entacapone, OR-611, was found to be a potent peripherally acting inhibitor of catechol-O-methyltransferase (COMT).	entacapone	0-10	catechol-O-methyltransferase	Rattus norvegicus	78-106
1407012-1	1992	Entacapone, OR-611, was found to be a potent peripherally acting inhibitor of catechol-O-methyltransferase (COMT).	entacapone	0-10	catechol-O-methyltransferase	Rattus norvegicus	108-112
1407012-1	1992	Entacapone, OR-611, was found to be a potent peripherally acting inhibitor of catechol-O-methyltransferase (COMT).	entacapone	12-18	catechol-O-methyltransferase	Rattus norvegicus	78-106
1407012-1	1992	Entacapone, OR-611, was found to be a potent peripherally acting inhibitor of catechol-O-methyltransferase (COMT).	entacapone	12-18	catechol-O-methyltransferase	Rattus norvegicus	108-112
1407012-4	1992	Entacapone showed reversible, tight-binding type of inhibition of soluble rat liver COMT with a Ki-value of 14 nmol/l and it also caused 50% inhibition of rat duodenal, erythrocyte, liver and striatal COMT activity 1 h after oral dosing with 1.1, 5.4, 6.7 and 24.2 mg/kg, respectively.	entacapone	0-10	catechol-O-methyltransferase	Rattus norvegicus	84-88
1407012-4	1992	Entacapone showed reversible, tight-binding type of inhibition of soluble rat liver COMT with a Ki-value of 14 nmol/l and it also caused 50% inhibition of rat duodenal, erythrocyte, liver and striatal COMT activity 1 h after oral dosing with 1.1, 5.4, 6.7 and 24.2 mg/kg, respectively.	entacapone	0-10	catechol-O-methyltransferase	Rattus norvegicus	201-205
1463794-0	1992	Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine.	entacapone	86-96	catechol-O-methyltransferase	Homo sapiens	46-74
1463794-7	1992	The assays were specific with respect to all known metabolites and selective, sensitive and precise enough for determination of entacapone and its Z-isomer in plasma and urine down to 10 ng ml-1.	entacapone	128-138	interleukin 17F	Homo sapiens	190-194
1875781-7	1991	The specific COMT inhibitors, nitecapone and OR-611, effectively inhibited in vitro the human intestinal COMT activity.	entacapone	45-51	catechol-O-methyltransferase	Homo sapiens	13-17
1875781-7	1991	The specific COMT inhibitors, nitecapone and OR-611, effectively inhibited in vitro the human intestinal COMT activity.	entacapone	45-51	catechol-O-methyltransferase	Homo sapiens	105-109
2289048-4	1990	COMT inhibitors nitecapone (OR-462) and OR-611 effectively inhibited human gastrointestinal COMT activity in vitro, the IC50 values ranging from 10-20 nM and 5-75 nM, respectively.	entacapone	40-46	catechol-O-methyltransferase	Homo sapiens	0-4
2289048-4	1990	COMT inhibitors nitecapone (OR-462) and OR-611 effectively inhibited human gastrointestinal COMT activity in vitro, the IC50 values ranging from 10-20 nM and 5-75 nM, respectively.	entacapone	40-46	catechol-O-methyltransferase	Homo sapiens	92-96
33269743-1	2021	Entacapone, a catechol-O-methyltransferase inhibitor, can strengthen the therapeutic effects of levodopa on the treatment of Parkinson"s disease.	entacapone	0-10	catechol-O-methyltransferase	Mus musculus	14-42
34619438-7	2021	In Period-2, the coadministration of entacapone with continuous ND0612 SC infusion translated to an increase in mean levodopa AUC0-10h compared to baseline.	entacapone	37-47	period circadian regulator 2	Homo sapiens	3-11
34225162-4	2021	It has been reported that 1-tetralone and 1-indanone derivatives are potent and specific inhibitors of MAO-B, while compounds containing the nitrocatechol moiety (e.g. tolcapone and entacapone) are often potent COMT inhibitors.	entacapone	182-192	catechol-O-methyltransferase	Homo sapiens	211-215
33269743-5	2021	Immunohistochemical staining results revealed that after entacapone treatment, the numbers of Ki67-positive proliferating cells, doublecortin-positive immature neurons, and phosphorylated cAMP response element-binding protein (pCREB)-positive cells were significantly increased.	entacapone	57-67	antigen identified by monoclonal antibody Ki 67	Mus musculus	94-98
33269743-5	2021	Immunohistochemical staining results revealed that after entacapone treatment, the numbers of Ki67-positive proliferating cells, doublecortin-positive immature neurons, and phosphorylated cAMP response element-binding protein (pCREB)-positive cells were significantly increased.	entacapone	57-67	doublecortin	Mus musculus	129-141
33269743-7	2021	Entacapone treatment antagonized the effects of TrkB receptor antagonist.	entacapone	0-10	neurotrophic tyrosine kinase, receptor, type 2	Mus musculus	48-52
35463646-2	2022	However, there have been negative effects reported against entacapone, namely, gastrointestinal (GI) problems and drowsiness.	entacapone	59-69	G protein subunit alpha i1	Homo sapiens	97-99
35563817-1	2022	The catechol-O-methyltransferase inhibitors entacapone and opicapone prolong the efficacy of conventional oral levodopa/dopa decarboxylase inhibitor formulations through an increase in levodopa plasma bioavailability.	entacapone	44-54	catechol-O-methyltransferase	Homo sapiens	4-32
35563817-1	2022	The catechol-O-methyltransferase inhibitors entacapone and opicapone prolong the efficacy of conventional oral levodopa/dopa decarboxylase inhibitor formulations through an increase in levodopa plasma bioavailability.	entacapone	44-54	dopa decarboxylase	Homo sapiens	120-138
35463646-1	2022	Background and Aims: Entacapone, one of the most common drugs distributed among patients with Parkinson"s disease, is a peripherally acting catechol-O-methyltransferase (COMT) inhibitor that is used in addition to levodopa to control symptoms.	entacapone	21-31	catechol-O-methyltransferase	Homo sapiens	140-168
35463646-1	2022	Background and Aims: Entacapone, one of the most common drugs distributed among patients with Parkinson"s disease, is a peripherally acting catechol-O-methyltransferase (COMT) inhibitor that is used in addition to levodopa to control symptoms.	entacapone	21-31	catechol-O-methyltransferase	Homo sapiens	170-174
35044481-3	2022	The available COMT inhibitors, entacapone, opicapone and tolcapone, differ pharmacokinetically in terms of their half-lives with implications for the dose frequency, in their indication requirements and in their spectrum of side effects, including diarrhea and yellow discoloration of urine.	entacapone	31-41	catechol-O-methyltransferase	Homo sapiens	14-18
34380879-6	2022	Here, we describe a subset of compounds containing a single aromatic ring, like dopamine, ZPDm, gallic acid, or entacapone, which act as molecular chaperones against alpha-synuclein aggregation.	entacapone	112-122	synuclein alpha	Homo sapiens	166-181
35121825-11	2022	Entacapone, a conventional drug for Parkinson"s disease, was confirmed to suppress OS via m6A-mediated regulation through the FTO/DACT1 axis.	entacapone	0-10	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	126-129
35121825-11	2022	Entacapone, a conventional drug for Parkinson"s disease, was confirmed to suppress OS via m6A-mediated regulation through the FTO/DACT1 axis.	entacapone	0-10	dishevelled binding antagonist of beta catenin 1	Homo sapiens	130-135
2501597-4	1989	The effect of catechol-O-methyltransferase (COMT) inhibitor, OR-611, on the potentiation of L-dopa-induced contralateral rotation in 6-OHDA-lesioned rats was also studied.	entacapone	61-67	catechol-O-methyltransferase	Rattus norvegicus	14-42
2501597-4	1989	The effect of catechol-O-methyltransferase (COMT) inhibitor, OR-611, on the potentiation of L-dopa-induced contralateral rotation in 6-OHDA-lesioned rats was also studied.	entacapone	61-67	catechol-O-methyltransferase	Rattus norvegicus	44-48
34017338-5	2021	We herein show that nanoparticle-mediated Fto-siRNA delivery or FTO inhibitor entacapone administration dramatically inhibited macrophage activation, reduced the tissue damage and improved survival in a mouse model of LPS-induced endotoxic shock.	entacapone	78-88	fat mass and obesity associated	Mus musculus	64-67
33352833-1	2020	Entacapone, a reversible inhibitor of catechol-O-methyl transferase, is used for patients in Parkinson"s disease because it increases the bioavailability and effectiveness of levodopa.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	38-67
33675481-3	2021	Entacapone is a catechol-O-methyl transferase (COMT) inhibitor which elicits antioxidant activity by scavenging peroxynitrite.	entacapone	0-10	catechol-O-methyltransferase	Rattus norvegicus	16-45
33675481-3	2021	Entacapone is a catechol-O-methyl transferase (COMT) inhibitor which elicits antioxidant activity by scavenging peroxynitrite.	entacapone	0-10	catechol-O-methyltransferase	Rattus norvegicus	47-51
33675481-9	2021	In addition, entacapone or FeTPPS significantly inhibited I/R-induced elevation in renal TNF-alpha levels (78% and 58%, respectively) and caspase-3 activity (72% and 56%, respectively) indicating the reduction of both inflammation and apoptosis in the kidney (P < 0.05).	entacapone	13-23	tumor necrosis factor	Rattus norvegicus	89-98
33675481-9	2021	In addition, entacapone or FeTPPS significantly inhibited I/R-induced elevation in renal TNF-alpha levels (78% and 58%, respectively) and caspase-3 activity (72% and 56%, respectively) indicating the reduction of both inflammation and apoptosis in the kidney (P < 0.05).	entacapone	13-23	caspase 3	Rattus norvegicus	138-147
33840171-2	2021	Additionally, several inhibitory drugs such as Entacapone and Opicapone are also cosupplemented to protect peripheral inactivation of exogenous L-DOPA (~80%) that occurs due to metabolic activity of the enzyme catechol-O-methyltransferase (COMT).	entacapone	47-57	catechol-O-methyltransferase	Homo sapiens	210-238
33840171-2	2021	Additionally, several inhibitory drugs such as Entacapone and Opicapone are also cosupplemented to protect peripheral inactivation of exogenous L-DOPA (~80%) that occurs due to metabolic activity of the enzyme catechol-O-methyltransferase (COMT).	entacapone	47-57	catechol-O-methyltransferase	Homo sapiens	240-244
33289420-0	2021	Tissue and interspecies comparison of catechol-O-methyltransferase mediated catalysis of 6-O-methylation of esculetin to scopoletin and its inhibition by entacapone and tolcapone.	entacapone	154-164	catechol-O-methyltransferase	Rattus norvegicus	38-66
33289420-3	2021	Furthermore, we compared the inhibition potencies and mechanisms of two clinically used COMT inhibitors, entacapone and tolcapone, in these species.	entacapone	105-115	catechol-O-methyltransferase	Rattus norvegicus	88-92
33289420-9	2021	Both entacapone and tolcapone are potent COMT inhibitors, but their inhibition mechanisms differ.	entacapone	5-15	catechol-O-methyltransferase	Rattus norvegicus	41-45
33136226-2	2021	The effect of entacapone on the pharmacokinetics of L-dopa differs between patients with high-activity (H/H) and low-activity (L/L) catechol-O-methyltransferase (COMT) Val158Met polymorphisms, but the effects are unclear in heterozygous (H/L) patients.	entacapone	14-24	catechol-O-methyltransferase	Homo sapiens	132-160
33136226-2	2021	The effect of entacapone on the pharmacokinetics of L-dopa differs between patients with high-activity (H/H) and low-activity (L/L) catechol-O-methyltransferase (COMT) Val158Met polymorphisms, but the effects are unclear in heterozygous (H/L) patients.	entacapone	14-24	catechol-O-methyltransferase	Homo sapiens	162-166
33136226-4	2021	Therefore, the present study aimed to clarify the effect of the COMT Val158Met polymorphism on the concentrations of L-dopa and 3-OMD in the presence of entacapone.	entacapone	153-163	catechol-O-methyltransferase	Homo sapiens	64-68
33352833-7	2020	In particular, entacapone significantly increased proteins related to synaptic trafficking and plasticity, such as dynamin 1, synapsin I, and Munc18-1.	entacapone	15-25	dynamin 1	Homo sapiens	115-124
33352833-7	2020	In particular, entacapone significantly increased proteins related to synaptic trafficking and plasticity, such as dynamin 1, synapsin I, and Munc18-1.	entacapone	15-25	synapsin I	Homo sapiens	126-136
33352833-7	2020	In particular, entacapone significantly increased proteins related to synaptic trafficking and plasticity, such as dynamin 1, synapsin I, and Munc18-1.	entacapone	15-25	syntaxin binding protein 1	Homo sapiens	142-150
32299731-7	2020	This is more potent than the reference COMT inhibitor, entacapone, which has an IC50 value of 0.23 muM.	entacapone	55-65	catechol-O-methyltransferase	Rattus norvegicus	39-43
33387482-10	2021	Interestingly, treatment with entacapone, which is used for the treatment of Parkinson"s disease and is an inhibitor of FTO, decreased HNF4alpha and UGT2B7 expression.	entacapone	30-40	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	120-123
33387482-10	2021	Interestingly, treatment with entacapone, which is used for the treatment of Parkinson"s disease and is an inhibitor of FTO, decreased HNF4alpha and UGT2B7 expression.	entacapone	30-40	hepatocyte nuclear factor 4 alpha	Homo sapiens	135-144
33387482-10	2021	Interestingly, treatment with entacapone, which is used for the treatment of Parkinson"s disease and is an inhibitor of FTO, decreased HNF4alpha and UGT2B7 expression.	entacapone	30-40	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	149-155
32750483-0	2020	Investigating the inhibitory effects of entacapone on amyloid fibril formation of human lysozyme.	entacapone	40-50	lysozyme	Homo sapiens	88-96
32750483-3	2020	In this study, we have investigated the inhibitory effect of entacapone (Ent) on human lysozyme (HL) amyloid fibrillation using a combination of biophysical techniques; Rayleigh scattering (RLS) data indicated that Ent can reduce the aggregation of HL amyloid fibrillation with the inhibition constant (Lambda) of (3.0 +- 0.5) x 103 M-1.	entacapone	61-71	lysozyme	Homo sapiens	87-95
32030869-10	2020	Additionally, the auxin response factor gene (GhARF3) located in inherited IBD segments from 108F and 611B, was highly correlated with fiber quality.	entacapone	102-106	auxin response factor 18-like	Gossypium hirsutum	46-52
32289635-5	2020	Second, in vitro assays confirmed the inhibitory effect of entacapone on maize COMT.	entacapone	59-69	caffeic acid 3-O-methyltransferase	Zea mays	79-83
31109396-10	2019	The known selective COMT inhibitor entacapone was used as test inhibitor.	entacapone	35-45	catechol-O-methyltransferase	Rattus norvegicus	20-24
31868682-10	2020	CONCLUSIONS: Independent from previous studies and prior assumptions we show that the currently-used LED conversion factors for immediate release levodopa, controlled release levodopa and amantadine are largely correct and that dopamine agonists, MAO-B inhibitors and entacapone, given in addition to levodopa, have little additional clinical value for PD patients with motor fluctuations.	entacapone	268-278	small integral membrane protein 10 like 2A	Homo sapiens	101-104
31837280-4	2020	Such biotransformation was completely blocked by entacapone, a well-known catechol-O-methyltransferase (COMT) inhibitor, demonstrating that the O-methylation was mediated by COMT.	entacapone	49-59	catechol-O-methyltransferase	Homo sapiens	74-102
31837280-4	2020	Such biotransformation was completely blocked by entacapone, a well-known catechol-O-methyltransferase (COMT) inhibitor, demonstrating that the O-methylation was mediated by COMT.	entacapone	49-59	catechol-O-methyltransferase	Homo sapiens	104-108
31837280-4	2020	Such biotransformation was completely blocked by entacapone, a well-known catechol-O-methyltransferase (COMT) inhibitor, demonstrating that the O-methylation was mediated by COMT.	entacapone	49-59	catechol-O-methyltransferase	Homo sapiens	174-178
31109396-11	2019	The results confirmed the ability of entacapone to inhibit COMT activity by decreasing the production of all the metabolites of norepinephrine.	entacapone	37-47	catechol-O-methyltransferase	Rattus norvegicus	59-63
30996080-0	2019	Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1.	entacapone	18-28	fat mass and obesity associated	Mus musculus	56-59
30996080-0	2019	Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1.	entacapone	18-28	forkhead box O1	Mus musculus	99-104
30996080-3	2019	Here, we used a structure-based virtual screening of U.S. Food and Drug Administration-approved drugs to identify entacapone as a potential FTO inhibitor.	entacapone	114-124	fat mass and obesity associated	Mus musculus	140-143
30996080-4	2019	Using structural and biochemical studies, we showed that entacapone directly bound to FTO and inhibited FTO activity in vitro.	entacapone	57-67	fat mass and obesity associated	Mus musculus	86-89
30996080-4	2019	Using structural and biochemical studies, we showed that entacapone directly bound to FTO and inhibited FTO activity in vitro.	entacapone	57-67	fat mass and obesity associated	Mus musculus	104-107
30996080-6	2019	We identified the transcription factor forkhead box protein O1 (FOXO1) mRNA as a direct substrate of FTO, and demonstrated that entacapone elicited its effects on gluconeogenesis in the liver and thermogenesis in adipose tissues in mice by acting on an FTO-FOXO1 regulatory axis.	entacapone	128-138	forkhead box O1	Mus musculus	39-62
30996080-6	2019	We identified the transcription factor forkhead box protein O1 (FOXO1) mRNA as a direct substrate of FTO, and demonstrated that entacapone elicited its effects on gluconeogenesis in the liver and thermogenesis in adipose tissues in mice by acting on an FTO-FOXO1 regulatory axis.	entacapone	128-138	forkhead box O1	Mus musculus	64-69
30996080-6	2019	We identified the transcription factor forkhead box protein O1 (FOXO1) mRNA as a direct substrate of FTO, and demonstrated that entacapone elicited its effects on gluconeogenesis in the liver and thermogenesis in adipose tissues in mice by acting on an FTO-FOXO1 regulatory axis.	entacapone	128-138	fat mass and obesity associated	Mus musculus	101-104
30996080-6	2019	We identified the transcription factor forkhead box protein O1 (FOXO1) mRNA as a direct substrate of FTO, and demonstrated that entacapone elicited its effects on gluconeogenesis in the liver and thermogenesis in adipose tissues in mice by acting on an FTO-FOXO1 regulatory axis.	entacapone	128-138	fat mass and obesity associated	Mus musculus	253-256
30996080-6	2019	We identified the transcription factor forkhead box protein O1 (FOXO1) mRNA as a direct substrate of FTO, and demonstrated that entacapone elicited its effects on gluconeogenesis in the liver and thermogenesis in adipose tissues in mice by acting on an FTO-FOXO1 regulatory axis.	entacapone	128-138	forkhead box O1	Mus musculus	257-262
30111624-4	2018	In this study, we expressed recombinant human UGT1A10 in human embryonic kidney (HEK)293 and Chinese hamster ovary (CHO) cells to examine its oligomeric states and characterize its enzymatic activities against two therapeutically interesting substrates, morphine and entacapone, including determination of the catalytic rate constant (kcat) values for the first time.	entacapone	267-277	UDP glucuronosyltransferase family 1 member A10	Homo sapiens	46-53
30135178-6	2018	All but two drugs showed substrate affinity to OAT2, whereas four (bromfenac, entacapone, fluorescein, and nateglinide) also showed OATP1B1 activity in transfected cells.	entacapone	78-88	solute carrier organic anion transporter family member 1B1	Homo sapiens	132-139
30111624-6	2018	Owing to the formation of the covalently crosslinked higher-order oligomers, the UGT1A10 protein expressed in HEK293 cells had much lower catalytic activity (particularly the catalytic rate constant kcat) against both morphine and entacapone, compared with the UGT1A10 protein form expressed in CHO cells against the same substrates.	entacapone	231-241	UDP glucuronosyltransferase family 1 member A10	Homo sapiens	81-88
30070707-5	2018	Entacapone is a clinically used inhibitor of COMT, and has been shown to modulate the methylation of food-derived polyphenols.	entacapone	0-10	catechol-O-methyltransferase	Homo sapiens	45-49
29688484-1	2018	Tolcapone and entacapone are catechol-O-methyltransferase inhibitors used in patients with Parkinson"s disease.	entacapone	14-24	catechol-O-methyltransferase	Homo sapiens	29-57
29696585-4	2018	In commercial oral formulations, LD is co-administrated with an AADC inhibitor (carbidopa) and a COMT inhibitor (entacapone) to enhance its bioavailability.	entacapone	113-123	catechol-O-methyltransferase	Homo sapiens	97-101
29697034-7	2018	The chalcone class of compounds is well known to potently inhibit MAO-B, while nitrocatechol derivatives (e.g. tolcapone and entacapone) are clinically used COMT inhibitors.	entacapone	125-135	catechol-O-methyltransferase	Homo sapiens	157-161
29614697-6	2018	OBJECTIVE: The primary aim of this study was to investigate the efficacy and safety of the two available COMT inhibitors; entacapone and tolcapone and the recently introduced opicapone.	entacapone	122-132	catechol-O-methyltransferase	Homo sapiens	105-109
28526448-0	2017	The catechol-O-methyltransferase inhibitors tolcapone and entacapone uncouple and inhibit the mitochondrial respiratory chain in HepaRG cells.	entacapone	58-68	catechol-O-methyltransferase	Homo sapiens	4-32